Navidea Biopharmaceuticals (NAVB) 10-K 15 Mar 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 01, 2019	Jun. 30, 2018
Document Information [Line Items]
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000810509
Trading Symbol	navb
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		200,690,700
Entity Public Float			$ 35,842,392
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 3,475,881	$ 2,795,006
Available-for-sale securities	799,270	1,797,604
Accounts and other receivables	21,151	8,137,872
Prepaid expenses and other	1,299,454	1,101,923
Total current assets	5,595,756	13,832,405
Property and equipment	1,251,185	1,206,058
Less accumulated depreciation and amortization	1,089,013	969,357
Property and equipment, net	162,172	236,701
License agreements, patents and trademarks	480,404	480,404
Less accumulated amortization	51,912	22,248
License agreements, patents and trademarks, net	428,492	458,156
Guaranteed earnout receivable		4,809,376
Other assets	835,107	1,444,798
Total assets	7,021,527	20,781,436
Current liabilities:
Accounts payable	424,718	855,043
Accrued liabilities and other	2,517,047	1,857,848
Notes payable	316,074	2,353,639
Terminated lease liability, current	120,679	107,215
Accrued loss for CRG litigation		2,887,566
Liabilities associated with discontinued operations, current		7,092
Total current liabilities	3,378,518	8,068,403
Terminated lease liability	468,494	588,092
Deferred revenue	700,000	11,024
Other liabilities	64,055	65,587
Total liabilities	4,611,067	8,733,106
Commitments and contingencies (Note 15)
Stockholders’ equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued or outstanding at December 31, 2018 and 2017
Common stock; $.001 par value; 300,000,000 shares authorized; 200,390,700 and 162,206,646 shares issued and outstanding at December 31, 2018 and 2017, respectively	200,391	162,207
Additional paid-in capital	338,265,383	331,128,787
Accumulated deficit	(336,722,905)	(319,908,968)
Accumulated other comprehensive loss	(730)	(2,396)
Total Navidea stockholders' equity	1,742,139	11,379,630
Noncontrolling interest	668,321	668,700
Total stockholders’ equity	2,410,460	12,048,330
Total liabilities and stockholders’ equity	$ 7,021,527	$ 20,781,436

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	200,390,700	162,206,646
Common stock, shares outstanding (in shares)	200,390,700	162,206,646

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Revenue:
Revenue from contract with customer		$ 338,000
Grant and other revenue		846,830	$ 1,701,311
Revenue		1,169,351	1,810,437
Cost of revenue		96,636	3,651
Gross profit		1,072,715	1,806,786
Operating expenses:
Research and development expenses		4,221,881	4,513,842
Selling, general and administrative		7,698,135	11,169,951
Total operating expenses		11,920,016	15,683,793
Loss from operations	[1]	(10,847,301)	(13,877,007)
Other expense:
Interest (expense) income, net		(30,799)	168,971
Change in fair value of financial instruments			153,357
Loss on extinguishment of debt		(5,291,616)	(4,201,668)
Other income (expense), net		1,145	(33,339)
Total other expense, net	[2]	(5,321,270)	(3,912,679)
Loss before income taxes		(16,168,571)	(17,789,686)
Benefit from income taxes		9,753	4,062,489
Loss from continuing operations		(16,158,818)	(13,727,197)
Discontinued operations, net of tax effect:
Income (loss) from discontinued operations		1,449	(490,758)
Gain on sale		43,053	89,163,811
Net (loss) income		(16,114,316)	74,945,856
Less loss attributable to noncontrolling interest		(379)	(210)
Net (loss) income attributable to common stockholders		$ (16,113,937)	$ 74,946,066
(Loss) income per common share (basic):
Continuing operations (in dollars per share)		$ (0.09)	$ (0.08)
Discontinued operations (in dollars per share)			0.55
Attributable to common stockholders (in dollars per share)		$ (0.09)	$ 0.47
Weighted average shares outstanding (basic) (in shares)		170,535,343	161,592,569
(Loss) income per common share (diluted):
Continuing operations (in dollars per share)		$ (0.09)	$ (0.08)
Discontinued operations (in dollars per share)			0.53
Attributable to common stockholders (in dollars per share)		$ (0.09)	$ 0.45
Weighted average shares outstanding (diluted) (in shares)		170,535,343	166,016,458
Royalty [Member]
Revenue:
Revenue from contract with customer		$ 15,347	$ 9,126
License [Member]
Revenue:
Revenue from contract with customer		$ 307,174	$ 100,000
[1]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.
[2]	Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Net (loss) income	$ (16,114,316)	$ 74,945,856
Unrealized gain (loss) on available-for-sale securities	1,666	(2,396)
Comprehensive (loss) income	$ (16,112,650)	$ 74,943,460

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' (Deficit) Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2016	155,762,729
Balance at Dec. 31, 2016	$ 155,763	$ 326,564,148	$ (394,855,034)		$ 468,910	$ (67,666,213)
Issued stock in payment of Board retainers (in shares)	16,406
Stock Issued During Period, Value, Issued for Services	$ 17	10,483				10,500
Issued stock in payment of employee bonuses (in shares)	710,353
Issued stock in payment of employee bonuses	$ 710	368,632				369,342
Issued stock upon exercise of warrants (in shares)	5,411,850
Issued stock upon exercise of warrants	$ 5,412	48,707				54,119
Issued warrants in connection with Asset Sale		3,337,187				3,337,187
Issued warrants for extension of license agreement		333,719				$ 333,719
Issued stock to 401(k) plan (in shares)	105,308					105,308
Issued stock to 401(k) plan	$ 105	53,602				$ 53,707
Issued restricted stock (in shares)	200,000
Issued restricted stock	$ 200					200
Canceled forfeited restricted stock (in shares)	(50,000)
Canceled forfeited restricted stock	$ (50)	50
Issued stock upon exercise of stock options (in shares)	50,000					50,000
Issued stock upon exercise of stock options	$ 50	18,050				$ 18,100
Stock compensation expense		394,209				394,209
Net income (loss)			74,946,066		(210)	74,945,856
Unrealized gain (loss) on available-for-sale securities				(2,396)		(2,396)
Total comprehensive income (loss)						74,943,460
Reclassification of funds invested (Note 10)					200,000	200,000
Balance (in shares) at Dec. 31, 2017	162,206,646
Balance at Dec. 31, 2017	$ 162,207	331,128,787	(319,908,968)	(2,396)	668,700	12,048,330
Issued stock in payment of employee bonuses (in shares)	1,118,760
Issued stock in payment of employee bonuses	$ 1,118	315,784				$ 316,902
Issued stock to 401(k) plan (in shares)	94,684					94,684
Issued stock to 401(k) plan	$ 95	35,885				$ 35,980
Issued restricted stock (in shares)	200,000
Issued restricted stock	$ 200					200
Canceled forfeited restricted stock (in shares)	(50,000)
Canceled forfeited restricted stock	$ (50)	50
Issued stock upon exercise of stock options (in shares)
Stock compensation expense		306,698				$ 306,698
Net income (loss)			(16,113,937)		(379)	(16,114,316)
Unrealized gain (loss) on available-for-sale securities				1,666		1,666
Total comprehensive income (loss)						(16,112,650)
Impact of adoption of ASC Topic 606 at Dec. 31, 2017			(700,000)			(700,000)
Issued stock pursuant to private placement (in shares)	18,320,610
Issued stock pursuant to private placement	$ 18,321	2,981,679				3,000,000
Issued stock pursuant to termination agreement (in shares)	18,500,000
Issued stock pursuant to termination agreement	$ 18,500	3,496,500				3,515,000
Balance (in shares) at Dec. 31, 2018	200,390,700
Balance at Dec. 31, 2018	$ 200,391	$ 338,265,383	$ (336,722,905)	$ (730)	$ 668,321	$ 2,410,460

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities:
Net (loss) income	$ (16,114,316)	$ 74,945,856
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization of property and equipment	120,721	232,339
Amortization of patents, trademarks and license agreements	29,664	22,248
Loss on disposal and abandonment of assets		807,241
Gain on forgiveness of accounts payable		(212,656)
Compounded interest on long term debt	153,390	265,196
Stock compensation expense	306,698	394,209
Change in fair value of financial instruments		(153,357)
Loss on extinguishment of debt	5,291,616	4,201,668
Issued warrants in connection with Asset Sale		3,337,187
Value of stock issued to directors		10,500
Value of stock issued to employees	616,902	369,342
Value of stock issued to 401(k) plan for employer matching contributions	35,980	53,707
Changes in operating assets and liabilities:
Accounts and other receivables	12,926,097	(11,145,238)
Inventory		1,470,826
Prepaid expenses and other assets	805,597	(934,536)
Accounts payable	(430,325)	(6,017,775)
Accrued liabilities and other liabilities	548,453	(6,248,179)
Deferred revenue	(15,037)	(2,315,037)
Net cash provided by operating activities	4,275,440	59,083,541
Cash flows from investing activities:
Purchases of available-for-sale securities	(600,000)	(2,200,000)
Proceeds from sales of available-for-sale securities	200,000
Maturities of available-for-sale securities	1,400,000	400,000
Purchases of equipment	(46,192)	(33,690)
Net cash provided by (used in) investing activities	953,808	(1,833,690)
Cash flows from financing activities:
Proceeds from issuance of common stock, net	3,000,200	72,419
Payment of debt-related costs	(7,153,000)	(1,314,102)
Principal payments on notes payable	(395,573)	(59,753,740)
Net cash used in financing activities	(4,548,373)	(60,995,423)
Net increase (decrease) in cash	680,875	(3,745,572)
Cash and cash equivalents, beginning of period	2,795,006	6,540,578
Cash and cash equivalents, end of period	$ 3,475,881	$ 2,795,006

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Organization and Summary of Significant Accounting Policies a. Organization and Nature of Operations: Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 Tc99m first On March 3, 2017, November 23, 2016, 414 ® November 15, 2007, 414 no Our consolidated balance sheets and statements of operations have been reclassified, as required, for all periods presented to reflect the Business as a discontinued operation. Cash flows associated with the operation of the Business have been combined with operating, investing and financing cash flows, as appropriate, in our consolidated statements of cash flows. Other than Tc99m none In January 2015, In July 2011, Tc99m 100% In December 2001, August 2009, 2013. not September 2017. b. Principles of Consolidation: c. Use of Estimates: d. Financial Instruments and Fair Value: 1 3 three Level 1 Level 2 not Level 3 A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. In determining the appropriate levels, we perform a detailed analysis of the assets and liabilities whose fair value is measured on a recurring basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no 3. 5. The following methods and assumptions were used to estimate the fair value of each class of financial instruments: ( 1 Cash and cash equivalents , available-for-sale securities, accounts and other receivables, and accounts payable: ( 2 Notes payable: December 31, 2018 2017 December 31, 2018, $316,000, $316,000. December 31, 2017, $2.4 $2.4 5 12. ( 3 Derivative liabilities: $63,000 December 31, 2018 2017 December 31, 2018 2017 5. ( 4 Warrants: March 2017, 414 five 10 1 $1.50 414 $3.3 December 31, 2017. $334,000, 16 e. Stock-Based Compensation: December 31, 2018, two 2002 “2002 2014 “2014 2014 may may 12 15 2002 no may Stock options granted under the 2002 2014 one four not ten 90 Stock-based payments to employees and directors, including grants of stock options, are recognized in the consolidated statement of operations based on their estimated fair values. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. Expected volatilities are based on the Company’s historical volatility, which management believes represents the most accurate basis for estimating expected future volatility under the current circumstances. Navidea uses historical data to estimate forfeiture rates. The expected term of stock options granted is based on the vesting period and the contractual life of the options. The risk-free rate is based on the U.S. Treasury yield in effect at the time of the grant. The assumptions used to calculate the fair value of stock option awards granted during the years ended December 31, 2018 2017 2018 2017 Expected volatility 64% - 76% 66% - 79% Weighted-average volatility 69% 75% Expected dividends — — Expected term (in years) 5.5 - 6.0 5.0 - 6.0 Risk-free rate 2.6% - 2.7% 1.8% - 2.1% The portion of the fair value of stock-based awards that is ultimately expected to vest is recognized as compensation expense over either ( 1 2 may not not 6. f. Cash and Cash Equivalents: three g. Available-for-Sale Securities: three h . Accounts and Other Receivable s : 8. i . Property and Equipment: 9. j . Intangible Assets: 5 15 no k . Impairment or Disposal of Long-Lived Assets: may not No December 31, 2018 2017. l . Leases: 14. m . Derivative Instruments: not one one not n . Revenue Recognition: We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 4. o . Research and Development Costs: p . Income Taxes: December 31, 2018 2017. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no December 31, 2018 2017 not twelve December 31, 2018, 2015 2018 17. q . Recently Adopted Accounting Standards: May 2014, 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09 2014 09 five may 2014 09, 606 2014 09, 2016 08, 2016 10, 2016 12 2016 20, January 1, 2018, 2014 09 $ 700,000 4. In November 2016, No. 2016 18, Statement of Cash Flows – Restricted Cash 2016 18 2016 18 December 15, 2017, 2016 18 2016 18 January 1, 2018. 2016 18 $5.0 December 31, 2017. In January 2017, No. 2017 01, Business Combinations (Topic 805 2017 01 not not not 2017 01 1 2 2017 01 December 15, 2017, 2017 01 No 2017 01. 2017 01 January 1, 2018. 2017 01 not In May 2017, No. 2017 09, Compensation-Stock Compensation (Topic 718 2017 09 1 not not 2 3 2017 09 December 15, 2017. 2017 09. 2017 09 January 1, 2018. 2017 09 not In March 2018, No. 2018 05, Income Taxes (Topic 740 No. 118 2018 05 740 No. 118. 2018 05 740 2018 05 March 2018 not r . Recent ly Issued Accounting Standards : February 2016, No. 2016 02, Leases (Topic 842 2016 02 842 2016 02 December 15, 2018, 2016 02, 2016 02 $ 286,000 In June 2018, No. 2018 07, Compensation—Stock Compensation (Topic 718 2018 07 718 718 2018 07 718 718 not 1 2 606, Revenue from Contracts with Customers 2018 07 December 15, 2018, 2018 07 not In July 2018, No. 2018 09, Codification Improvements 2018 09 2018 09 December 15, 2018 2018 09 not Also in July 2018, No. 2018 10, Codification Improvements to Topic 842, No. 2018 11, Targeted Improvements to Topic 842, 2018 10 842 2016 02, Leases (Topic 842 2018 11 840, Leases 840 840. 2018 10 2018 11 2016 02 December 15, 2018. not 2018 10 2018 11 In August 2018, No. 2018 13, Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018 13 280, 2018 13 1 1 2 2 3 3 4 3 2018 13 1 3 3 3 2 3 2018 13 1 3 2 3 2018 13 December 15, 2019. not 2018 13 may

Note 2 - Liquidity

Note 2 - Liquidity	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Liquidity The Company is engaged in ongoing litigation with CRG, and is currently pursuing recovery of $4.1 $1.9 October 31, 2018, 12 15. Effective August 14, 2018, one $978,000 two one $35,000, 16 23.5 November 20, 2018, 18.5 5.0 15. On September 13, 2018, 18,320,610 $3.0 16 The Company is currently engaged in litigation with CRG and Dr. Goldberg. In addition, the Company has experienced recurring net losses and has used significant cash to fund its operations. The Company has considerable discretion over the extent of development project expenditures and have the ability to curtail the related cash flows as needed. The Company also has funds remaining under outstanding grant awards, and continues working to establish new sources of funding, including collaborations, potential equity investments, and additional grant funding that can augment the balance sheet. However, based on our current working capital and our projected cash burn, and without definitive agreements in place for additional funding, management believes that there is substantial doubt about the Company’s ability to continue as a going concern for at least twelve 10

Note 3 - Discontinued Operation

Note 3 - Discontinued Operations	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	3. Discontinued Operations On March 3, 2017, 414 ® 414 $80.6 $3.0 On April 2, 2018, 414 $6.0 not $7.1 414 414 414 April 9, 2018, $7.1 $4.1 $59.0 We recorded a net gain on the sale of the Business of $89.2 December 31, 2017, $16.5 $3.3 414, $2.0 $800,000 $4.1 $43,000 December 31, 2018, $54,000 $11,000 As a result of the Asset Sale, we reclassified certain assets and liabilities as assets and liabilities associated with discontinued operations. The following liabilities have been segregated and included in liabilities associated with discontinued operations, as appropriate, in the consolidated balance sheets: December 31 , 2018 December 31, 2017 Accrued liabilities $ — $ 7,092 Liabilities associated with discontinued operations, current $ — $ 7,092 In addition, we reclassified certain revenues and expenses related to the Business to discontinued operations for all periods presented, including interest expense related to the CRG and Platinum debt obligations as required by current accounting guidance. The following amounts have been segregated from continuing operations and included in discontinued operations in the consolidated statements of operations: Years Ended December 31, 2018 2017 Lymphoseek sales revenue $ — $ 2,917,213 Cost of goods sold — 364,192 Gross profit — 2,553,021 Operating expenses: Research and development (1,835 ) 383,446 Selling, general and administrative — 961,873 Total operating expenses (1,835 ) 1,345,319 Income from discontinued operations 1,835 1,207,702 Interest expense — (1,706,491 ) Income (loss) before income taxes 1,835 (498,789 ) (Provision for) benefit from income taxes (385 ) 8,031 Income (loss) from discontinued operations $ 1,450 $ (490,758 )

Note 4 - Revenue From Contracts

Note 4 - Revenue From Contracts With Customers	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	4 . Revenue from Contracts with Customers The Company adopted ASU 2014 09, January 1, 2018, December 31, 2018 January 1, 2018 not January 1, 2018. We earn revenues related to our licensing and distribution agreements. The terms of these agreements may The cumulative effect of the change on accumulated deficit as of January 1, 2018 $700,000, $100,000 Tc99m June 2017, $600,000 Tc99m August 2014. not Pre- Adoption Post-Adoption Change Deferred revenue $ 26,061 $ 726,061 $ 700,000 Accumulated deficit (319,908,968 ) (320,608,968 ) (700,000 ) During the year ended December 31, 2018, $338,000. not Navidea is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. We manage our business based on two Tc99m Tc99m one Tc99 In April 2018, NAV4694, NAV4694 The following tables disaggregate the Company’s revenue from contracts with customers for the year ended December 31, 2018. Year Ended Dec ember 3 1 , 2018 Diagnostics Therapeutics Total Royalty revenue: Europe $ 15,347 $ — $ 15,347 India — — — China — — — Total $ 15,347 $ — $ 15,347 License revenue: NAV4694 sublicense $ 287,569 $ — $ 287,569 Tc99m tilmanocept sublicense, China 19,605 — 19,605 Total $ 307,174 $ — $ 307,174 Other revenue: Additional stability studies $ 15,037 $ — $ 15,037 The following economic factors affect the nature, amount, timing and uncertainty of the Company’s revenue and cash flows as indicated: Geographical Location of Customers: may may Tc99m Status of Regulatory Approval: Tc99m Tc99m Tc99m not may NAV4694 not The following table summarizes the changes in contract liabilities, the current portion of which is included in accrued liabilities and other in the consolidated balance sheets, during the years ended December 31, 2018 2017: Year Ended Dec ember 3 1 , 2018 2017 Total deferred revenue, beginning of period $ 26,061 $ 41,098 Impact of adoption of ASU 2014-09 and related standards 700,000 — Revenue deferred related to sublicense 10,000 — Revenue recognized from satisfaction of performance obligations (25,037 ) (15,037 ) Total deferred revenue, end of period $ 711,024 $ 26,061 Currently, the Company recognizes revenue from up-front license fees and pre-market milestones after the cash has been received from its customers and the performance obligations have been met. Payments for sales-based royalties and milestones are generally received after the related revenue has been recognized and invoiced. Normal payment terms generally range from 15 90 $12,000 December 31, 2018. During the year ended December 31, 2018, not Up-front and milestone payments received related to our license and distribution agreements in India and China are deferred until Tc99m not Tc99m not no not eight 10 The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. Transaction prices do not third not When estimating a contract’s transaction price, the Company considers all the information (historical, current, and forecasted) that is reasonably available to it and identifies possible consideration amounts. Most of the Company’s contracts with customers include both fixed and variable components of the transaction price. Under those contracts, some or all of the consideration for satisfied performance obligations is contingent on events over which the Company has no Tc99m The milestone payments have a binary outcome (that is, the Company will either receive all or none not Royalties are estimated based on the expected value method because they are based on a variable amount of sales representing a range of possible outcomes. However, when taking into account the constraint on variable consideration, the estimate of future royalties included in the transaction price is generally $0. Tc99m not no no The sublicense of NAV4694 Up-front fees, milestones and royalties are generally non-refundable. Therefore, the Company does not Through December 31, 2018, not In addition to revenue from contracts from customers, we also generate revenue from NIH grants to support various product development initiatives. The new revenue recognition standard applies to revenue from contracts with customers. A customer is defined as a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ongoing major or central operations in exchange for consideration. The Company’s ongoing major or central operations consist of the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The NIH and its various institutes are responsible for biomedical and public health research and provide major biomedical research funding to non-NIH research facilities and entities such as Navidea. While the Company will directly benefit from any knowledge gained from the project, there is also a public health benefit provided, which justifies the use of public funds in the form of the grants. Based on the nature of the Company’s operations and the terms of the grant awards, Navidea and the NIH do not not January 1, 2018.

Note 5 - Fair Value

Note 5 - Fair Value	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	5. Fair Val ue The Company’s available-for-sale securities consist of certificates of deposit which are measured using Level 2 MT issued warrants to purchase MT Common Stock with certain characteristics including a net settlement provision that require the warrants to be accounted for as a derivative liability at fair value on the consolidated balance sheets. The estimated fair value of the MT warrants is $63,000 December 31, 2018 2017, 1 10. The following table sets forth, by level, financial assets and liabilities measured at fair value on a recurring basis: Assets and Liabilities Measured at Fair Value on a Recurring Basis as of December 31, 2018 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Certificates of deposit $ — $ 799,270 $ — $ 799,270 Liabilities: Liability related to MT warrants $ — $ — $ 63,000 $ 63,000 Assets and Liabilities Measured at Fair Value on a Recurring Basis as of December 31, 2017 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Certificates of deposit $ — $ 1,797,604 $ — $ 1,797,604 Liabilities: Liability related to MT warrants $ — $ — $ 63,000 $ 63,000 a. Valuation Processes-Level 3 third b. Sensitivity Analysis-Level 3 may may not There were no 1 2 December 31, 2018 2017. no 1 2 December 31, 2018 2017. 3 3 December 31, 2017 $153,000.

Note 6 - Stock-based Compensati

Note 6 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	6 . Stock-Based Compensation For the years ended December 31, 2018 2017, $307,000 $394,000, not December 31, 2018 2017. A summary of the status of our stock options as of December 31, 2018, Year Ended December 31, 201 8 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at beginning of year 3,687,679 $ 1.50 Granted 470,000 0.53 Exercised — — Canceled and forfeited (992,510 ) 1.86 Expired (7,000 ) 0.66 Outstanding at end of year 3,158,169 $ 1.24 6.6 $ — Exercisable at end of year 1,502,173 $ 1.87 4.4 $ — The weighted average grant-date fair value of options granted in 2018 2017 $0.20 $0.19, 2017, 50,000 $4,400 50,000 $18,100. No 2018. 2018 2017, $0 A summary of the status of our unvested restricted stock as of December 31, 2018, Year Ended December 31, 201 8 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of year 150,000 $ 0.51 Granted 200,000 0.37 Forfeited (50,000 ) 0.36 Vested (200,000 ) 0.47 Unvested at end of year 100,000 $ 0.37 During 2018 2017, 200,000 207,000 $59,000 $99,000, In March 2018, 100,000 $36,000 August 2018, 50,000 $7,000 2018, 100,000 $23,000 In October 2017, 50,000 $22,000 2017, 140,000 $65,000 2017, 17,000 $9,000, 50,000 $25,000, not As of December 31, 2018, $71,000 1.2 1

Note 7 - (Loss) Earnings Per Sh

Note 7 - (Loss) Earnings Per Share	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	7 . (Loss) Earnings Per Share Basic (loss) earnings per share is calculated by dividing net (loss) income attributable to common stockholders by the weighted-average number of common shares and, except for periods with a loss from operations, participating securities outstanding during the period. Diluted (loss) earnings per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may The following table sets forth the reconciliation of the weighted average number of common shares outstanding used to compute basic and diluted earnings (loss) per share for the years ended December 31, 2018 2017: 2018 2017 Weighted average shares outstanding, basic 170,535,343 161,592,569 Dilutive shares related to warrants — 4,273,889 Unvested restricted stock — 150,000 Weighted average shares outstanding, diluted 170,535,343 166,016,458 Diluted (loss) earnings per common share for the years ended December 31, 2018 2017 17.9 14.5 The Company’s unvested stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 100,000 150,000 December 31, 2018 2017,

Note 8 - Accounts and Other Rec

Note 8 - Accounts and Other Receivables and Concentrations of Credit Risk	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	8 . Accounts and Other Receivables and Concentrations of Credit Risk Accounts and other receivables at December 31, 2018 2017 201 8 201 7 Guaranteed earnout receivable, current $ — $ 8,084,392 Trade 12,378 — Other 8,773 53,480 Total accounts and other receivables $ 21,151 $ 8,137,872 At December 31, 2018, 47% December 31, 2017, 99% 414. December 31, 2018 2017, no not 1

Note 9 - Property and Equipment

Note 9 - Property and Equipment	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	9 . Property and Equipment The major classes of property and equipment are as follows: Useful Life (in years) 201 8 201 7 Production machinery and equipment 3 – 5 $ 575,091 $ 575,091 Other machinery and equipment, primarily computers and research equipment 5 323,259 293,757 Furniture and fixtures 7 4,327 4,327 Purchased software 3 336,060 320,435 Leasehold improvements* Term of Lease 12,448 12,448 Total property and equipment $ 1,251,185 $ 1,206,058 * We amortize leasehold improvements over the term of the lease, which in all cases is shorter than the estimated useful life of the asset. No December 31, 2018 2017. 2018 2017, $121,000 $232,000, 1

Note 10 - Investment in Macroph

Note 10 - Investment in Macrophage Therapeutics, Inc.	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Investments in and Advances to Affiliates, Schedule of Investments [Text Block]	10 . Investment in Macrophage Therapeutics, Inc. In March 2015, 50 1,500 $50,000 one 30 40% 50 may 1% March 11, 2015, first 10 300 $500,000. The warrants have certain characteristics including a net settlement provision that require the warrants to be accounted for as a derivative liability at fair value, with subsequent changes in fair value included in earnings. The fair value of the warrants was estimated to be $63,000 December 31, 2018 2017. 1 5. $2.0 $113,000 In addition, we entered into a Securities Exchange Agreement with the MT Investors providing them an option to exchange their MT Preferred Stock for our common stock in the event that MT has not $50 second $50,000 80% twenty second $3.00. not $58,320 In December 2015 May 2016, $200,000 not $200,000 In July 2016, $300,000 $200,000 10% $500 first $200,000 December 2015 May 2016. $200,000 December 31, 2017. 10 not In August 2018, 5% 10 not On February 11, 2019, February 19, 2019, March 1, 2019 February 20, 2019, may On February 20, 2019, February 20, 2019, March 13, 2019, may not On March 7, 2019, 23.5 15.

Note 11 - Accounts Payable, Acc

Note 11 - Accounts Payable, Accrued Liabilities and Other	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	1 1 . Accounts Payable, Accrued Liabilities and Other At December 31, 2017, $96,000 December 31, 2016. Accrued liabilities and other at December 31, 2018 2017, $1.6 $975,000 201 8 201 7 Compensation $ 1,637,337 $ 915,672 Contracted services 866,934 923,115 Other 12,776 19,061 Total accrued liabilities and other $ 2,517,047 $ 1,857,848

Note 12 - Notes Payable

Note 12 - Notes Payable	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	1 2 . Notes Payable Platinum In July 2012, $50.0 Tc99m $35.0 $15.0 June 25, 2013, $8.0 In June 2013, $35.0 6.75%; 10.0%; 0.125%. In connection with the First Platinum Amendment, the Company and Platinum entered into a Warrant Exercise Agreement (“Exercise Agreement”), pursuant to which Platinum exercised its Series X $4.8 2,364.9 7,733,223 3,270 In March 2014, second 6.75%, 10.0%, 0.125%. In May 2015, six 6.75%, 10.0% 0.125%; not ten $2.53 In accordance with the terms of a Section 16 6%, July 1, 2016. December 31, 2018 2017, $153,000 $265,000, In connection with the closing of the Asset Sale to Cardinal Health 414 March 2017, $7.7 15. The Platinum Note is reflected on the consolidated balance sheets at its principal balance plus the estimated fair value of the embedded conversion option of $0 December 31, 2018 2017. December 31, 2018 2017, $0 $153,000, $0 $2.0 December 31, 2018 2017, Capital Royalty Partners II, L.P. In May 2015, $50.0 $10.0 May 15, 2015 ( 14.0%. March 31, 2019, 10.00% 4.00% 2015 2016, $1.8 June 30, 2015. eight two March 31, 2021. April 2016, second 2016 The CRG Term Loan was collateralized by a security interest in substantially all of the Company's assets. In addition, the CRG Loan Agreement required that the Company adhere to certain affirmative and negative covenants, including financial reporting requirements and a prohibition against the incurrence of indebtedness, or creation of additional liens, other than as specifically permitted by the terms of the CRG Loan Agreement. The Lenders could accelerate the payment terms of the CRG Loan Agreement upon the occurrence of certain events of default set forth therein, which include the failure of the Company to make timely payments of amounts due under the CRG Loan Agreement, the failure of the Company to adhere to the covenants set forth in the CRG Loan Agreement, and the insolvency of the Company. The covenants of the CRG Loan Agreement included a covenant that the Company shall have EBITDA of no $5.0 Tc99m $22.5 2016, $45.0 2020. 2.5 $5.0 14% 18% During the course of 2016, April 7, 2016. June 22, 2016, one $4.1 $3.9 $189,000 2016 2017. On March 3, 2017, 414. March 3, 2017, $59.0 Following a trial in December 2017, $66.0 $66.0 $59.0 March 2017, $7.0 not June 2016 $4.1 $66.0 $4.1 April 2018, $7.1 $4.1 $59.0 $4.1 $7.0 $4.1 15. I PFS Corporation In November 2017, $396,000 4.0%. ten $40,000, August 2018. November 2018, $393,000 5.1%. ten $40,000, August 2019. Interest expense related to the IPFS notes payable totaled $8,000 $12,000 December 31, 2018 2017, $316,000 $318,000 December 31, 2018 2017, Summary During the years ended December 31, 2018 2017, $161,000 $159,000, $153,000 $134,000 December 31, 2018 2017. Interest expense in the amount of $1,706,491 December 31, 2017 3. Annual principal maturities of our notes payable are $316,000 2019.

Note 13 - Terminated Lease Liab

Note 13 - Terminated Lease Liability	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Terminated Lease Liability Disclosure [Text Block]	1 3 . Terminated Lease Liability Effective June 1, 2017, 5600 4995 no October 2022. In accordance with current accounting guidance, the Company initially recorded a total liability of $1.0 $399,000 $706,000. December 31, 2017. A summary of the changes in our terminated lease liability during the year ended December 31, 2018 Terminated Lease Liability Total liability, January 1, 2018 $ 695,307 Changes in estimated future payments (43,393 ) Payments under Blazer lease (491,031 ) Receipts from subtenant 391,242 Accretion of liability 37,048 Total liability, December 31, 2018 $ 589,173

Note 14 - Leases

Note 14 - Leases	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Leases of Lessee Disclosure [Text Block]	1 4 . Leases We currently lease approximately 5,000 4995 June 2020, $3,000. 2,000 560 March 2019, $3,000. In addition, we currently lease approximately 25,000 5600 October 2022, $26,000 2019. June 2017, $39,000 October 2022. We also currently lease a vehicle. The lease term expires in September 2021, $300. As of December 31, 2018, December 31 Operating Leases 2019 $ 339,202 2020 319,034 2021 306,781 2022 253,339 Total future minimum lease payments $ 1,218,356 Total rental expense was $68,000 $139,000 December 31, 2018 2017, 1

Note 15 - Commitments and Conti

Note 15 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	1 5 . Commitments and Contingencies We are subject to legal proceedings and claims that arise in the ordinary course of business. Sinotau Litigation – NAV4694 On August 31, 2015, NAV4694 September 2016, In October 2017, NAV4694, NAV4694 not In April 2018, NAV4694, NAV4694 September 2018. CRG Litigation Prior to the Asset Sale to Cardinal Health 414 March 2017, 14% 18% 2016, June 22, 2016, one $4.1 2016 2017. On March 3, 2017, 414 February 22, 2017. March 3, 2017, $59.0 no no $47.0 no $66.0 414 $7.0 414’s $12.0 March 3, 2017, $59.0 March 3, 2017, 414 $7.0 March 7, 2017, $12.0 Following a trial in December 2017, $66.0 $66.0 $59.0 March 2017, $7.0 not June 2016 $4.1 $66.0 $4.1 $4.1 $7.0 On January 16, 2018, $66.0 $4.1 June 2016, $2.9 March 26, 2018, $7.7 April 2, 2018, $4.1 June 2016 $66.0 2019. November 21, 2018. 2019. On April 9, 2018, $7.1 $4.1 $59.0 On April 12, 2018 2017, $66.0 $66.0 $4.1 June 2016 $66.0 $66.0 $7.1 414 May 22, 2018 June 26, 2018 August 16, 2018, $4.1million August 27, 2018, 2019. In a related proceeding before the Ohio Court, initially filed in 2016, 2017, $66.0 not $4.1 $4.1 April 12, 2018 On April 11, 2018, not $7.1 414 April 16, 2018, April 27, 2018. August 17, 2018, 2019. On July 11, 2018, first not 12. Former CEO Arbitration On May 12, 2016 4G May 9, 2016. May 13, 2016, 4G May 12, 2017, April 7, 2016. $481,039 $617,880 May 16, 2017. FTI Consulting, Inc. Litigation On October 11, 2016, $782,600 $730,264 $52,337 November 14, 2016, February 7, 2017, June 26, 2017, June 2017, $862,165 $435,000 June 30, 2017. Sinotau Litigation – Tc99m Tilmanocept On February 1, 2017, Tc99m 414. February 3, 2017, March 6, 2017. March 3, 2017. March 6, 414 February 2, 2017. July 12, 2017, July 27, 2017 60 February 8, 2018, February 17, 2018, February 20, 2018, Platinum-Montaur Life Sciences LLC On November 2, 2017, $1.9 March 3, 2017, December 6, 2017. January 26, 2018 March 9, 2018, April 6, 2018. October 31, 2018, no On November 30, 2018, January 22, 2019, February 26, 2019, not 12. Goldberg Agreement Effective August 14, 2018, one $978,000 two one $35,000 16 23.5 23.5 18 5% November 20, 2018, 18.5 5.0 10 not On February 11, 2019, February 19, 2019, March 1, 2019 February 20, 2019, may On February 20, 2019, February 20, 2019, March 13, 2019, may not On March 7, 2019, 23.5 22. NYSE American Continued Listing Standards On August 14, 2018, not not 1003 $4.0 three four $2.1 June 30, 2018, four five December 31, 2017. Navidea was required to submit a plan to the NYSE American by September 14, 2018 February 14, 2020. On October 25, 2018, not 1003 $6.0 five $2.1 June 30, 2018, five December 31, 2017. The Company must provide quarterly updates to the NYSE American staff (the “Staff”) concurrent with its interim/annual SEC filings. If Navidea fails to regain compliance with the stockholders’ equity standards by February 14, 2020, may In addition, the Deficiency Letter stated that the Staff determined that the Company’s securities have been selling for a low price per share for a substantial period of time and, pursuant to Section 1003 $0.001 February 14, 2019 1003 In August 2018, not one five not one On January 28, 2019, March 31, 2019 1003 February 14, 2020. In accordance with ASC Topic 450, Contingencies not

Note 16 - Equity Instruments

Note 16 - Equity Instruments	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	1 6 . Equity Instruments a. Common Stock Issued: September 2018, 18,320,610 $0.001 $3.0 During November 2018, 18,500,000 August 2018 5,000,000 15. During the years ended December 31, 2018 2017, 1,118,760 710,353 $317,000 $369,000, 2017, 2016 2015 During the years ended December 31, 2018 2017, 94,684 105,308 401 $36,000 $54,000, During the year ended December 31, 2017, 16,406 $10,500 not December 31, 2018. b. Stock Warrants: December 31, 2018, 16.4 $0.01 $2.50 $1.15. 0.7 16.6 The following table summarizes information about our outstanding warrants at December 31, 2018: Exercise Price Number of Warrants Expiration Date Series HH 2.49 301,205 June 2023 Series KK 1.918 391,032 March 2021 Series LL 0.01 4,365,280 August 2035 Series MM 2.50 150,000 September 2019 Series MM 2.50 150,000 October 2019 Series NN 1.50 11,000,000 March 2022 Total warrants $ 1.15 * 16,357,517 * Weighted average exercise price. In addition, at December 31, 2018, 300 $2,000 In January 2017, 5,411,850 5,411,850 $54,119. In March 2017, 414 five 10 1 $1.50 five 77.0% five 2.0%. 414 $3.3 December 31, 2017. $334,000, December 30, 2017. c. Common Stock Reserved: December 31, 2018, 19,515,686 5,000,000 August 2018 15.

Note 17 - Income Taxes

Note 17 - Income Taxes	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	1 7 . Income Taxes As of December 31, 2018 2017, $41.6 $39.7 As of December 31, 2018 2017 Deferred tax assets: Net operating loss carryforwards $ 29,597,313 $ 29,570,581 R&D credit carryforwards 9,067,874 10,043,714 AMT credit carryforward 621,240 1,229,979 Stock compensation 375,731 576,024 Intangibles 550,797 591,651 Gain/loss from discontinued operations — (2,510,699 ) Disallowed interest expense 878,929 — Temporary differences 480,888 207,447 Deferred tax assets before valuation allowance 41,572,772 39,708,697 Valuation allowance (40,951,532 ) (38,478,718 ) Net deferred tax assets $ 621,240 $ 1,229,979 Current accounting standards require a valuation allowance against DTAs if, based on the weight of available evidence, it is more likely than not may not December 31, 2018 2017 In assessing the realizability of DTAs, management considers whether it is more likely than not not not not December 31, 2018, The Tax Cuts and Jobs Act (the “Tax Act”) was signed into law on December 22, 2017. 35% 21%, January 1, 2018. $26.4 $26.4 December 31, 2017. 2018, 2019 2020. may 2018 2020, 50% 2018, 2019 2020 2021. $1.2 December 31, 2017. 50% $1.2 December 31, 2018. As of December 31, 2018 2017, $130.9 $131.8 $15.1 December 31, 2018, not December 31, 2017, 2016 09 As of December 31, 2018 2017, $20.3 $20.4 2032. At December 31, 2018 2017, $8.7 $9.7 There were no 2018 2017. $1.2 2018. no 2017. As of December 31, 201 8 Generated Expiration U.S. Net Operating Loss Carryforwards U.S. R&D Credit Carryforwards 1999 2019 $ — $ 130,359 2000 2020 — 71,713 2001 2021 — 39,128 2002 2022 — 5,350 2003 2023 — 2,905 2004 2024 — 22,861 2005 2025 — 218,332 2006 2026 — 365,541 2007 2027 — 342,898 2008 2028 — 531,539 2009 2029 — 596,843 2010 2030 — 1,094,449 2011 2031 — 1,950,744 2012 2032 18,684,249 468,008 2013 2033 37,450,522 681,772 2014 2034 34,088,874 816,116 2015 2035 25,073,846 492,732 2016 2036 15,581,209 262,257 2017 2037 — 387,892 2018 2038 — 197,547 Total carryforwards $ 130,878,700 $ 8,678,986 During the year ended December 31, 2017, $5,000. December 31, 2016, $7.7 not December 31, 2016. September 2017 Under Sections 382 383 1986, may 382 2017 not 382 Reconciliations between the statutory federal income tax rate and our effective tax rate for continuing operations are as follows: 2018 2017 Amount % Amount % Benefit at statutory rate $ (3,383,491 ) (21.0 )% $ (6,048,423 ) (34.0 )% Adjustments to valuation allowance 2,458,580 15.3 % (26,080,051 ) (146.6 )% Adjustments to R&D credit carryforwards 975,840 6.1 % (291,745 ) (1.6 )% Tax law changes — — 28,731,045 161.5 % Permanent items and other (60,682 ) (0.3 )% (373,315 ) (2.2 )% Benefit per financial statements $ (9,753 ) $ (4,062,489 ) See Note 1

Note 18 - Segments

Note 18 - Segments	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	1 8 . Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no two Tc99m NAV4694 April 2018), The information in the following tables is derived directly from each reportable segment’s financial reporting. Certain revenue and expense amounts in the year ended December 31, 2017 3. Year Ended December 31, 2018 Diagnostics Therapeutics Corporate Total Royalty revenue $ 15,347 $ — $ — $ 15,347 License revenue 307,174 — — 307,174 Grant and other revenue 494,997 351,833 — 846,830 Total revenue 817,518 351,833 — 1,169,351 Cost of revenue 96,636 — — 96,636 Research and development expenses 3,064,115 1,157,766 — 4,221,881 Selling, general and administrative expenses, excluding depreciation and amortization (a) — 78,606 7,469,144 7,547,750 Depreciation and amortization (b) — — 150,385 150,385 Loss from operations (c) (2,343,233 ) (884,539 ) (7,619,529 ) (10,847,301 ) Other expense (d) — — (5,321,270 ) (5,321,270 ) Benefit from income taxes 1,413 534 7,806 9,753 Loss from continuing operations (2,341,820 ) (884,005 ) (12,932,993 ) (16,158,818 ) Income from discontinued operations, net of tax effect 1,449 — — 1,449 Gain on sale of discontinued operations, net of tax effect 43,053 — — 43,053 Net loss (2,297,318 ) (884,005 ) (12,932,993 ) (16,114,316 ) Total assets, net of depreciation and amortization: United States $ 91,425 24,763 6,878,129 6,994,317 International 14,330 381 14,711 Capital expenditures — — 46,192 46,192 Year Ended December 31, 2017 Diagnostics Therapeutics Corporate Total Royalty revenue $ 9,126 $ — $ — $ 9,126 License revenue 100,000 — — 100,000 Grant and other revenue 1,506,232 195,079 — 1,701,311 Total revenue 1,615,358 195,079 — 1,810,437 Cost of revenue 3,651 — — 3,651 Research and development expenses, excluding depreciation and amortization 3,784,255 729,587 — 4,513,842 Selling, general and administrative expenses, excluding depreciation and amortization (a) — 34,484 10,895,301 10,929,785 Depreciation and amortization (b) — — 240,166 240,166 Loss from operations (c) (2,172,548 ) (568,992 ) (11,135,467 ) (13,877,007 ) Other income (expense) (d) — — (3,912,679 ) (3,912,679 ) Benefit from income taxes 496,127 129,936 3,436,426 4,062,489 Loss from continuing operations (1,676,421 ) (439,056 ) (11,611,720 ) (13,727,197 ) Income from discontinued operations, net of tax effect 88,673,053 — — 88,673,053 Net income (loss) 86,996,632 (439,056 ) (11,611,720 ) 74,945,856 Total assets, net of depreciation and amortization: United States $ 13,065,871 $ 49,001 $ 7,634,237 $ 20,749,109 International 30,476 — 1,851 32,327 Capital expenditures — — 33,690 33,690 (a) General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not (b) Depreciation and amortization is reflected in selling, general and administrative expenses ( $150,385 $240,166 December 31, 2018 2017, (c) Loss from operations does not (d) Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not

Note 19 - Agreements

Note 19 - Agreements	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Significant Agreements Disclosure [Text Block]	1 9 . Agreements a. Supply Agreements: November 2009, Tc99m ten November 2019, three not 60 $0 December 31, 2018 2017. 414, 414. In September 2013, Tc99m not 60 Tc99m $0 $250,000 December 31, 2018 2017, 414, 414. Also in September 2013, three one $0 $14,000 December 31, 2018 2017, Tc99m b. Research and Development Agreements January 2002, Tc99m July 2014, third $25,000 $25,000 $25,000 Tc99m $1,000 $4,000 2018 2017, In connection with the March 2017 414, Tc99m 414 414 414 2017 five 5 1 $.001 $1.50 $35,000 $34,000 2018 2017, In July 2014, Tc99m third may $25,000 $25,000 $25,000 $250,000 $253,000 2018 2017, In December 2011, NAV4694, tenth first NAV4694 NAV4694 $5.0 $6.5 $11.0 $0 70,000 2018 2017, c. Employment Agreements: December 31, 2018, one 4.25 December 31, 2018, $2.0

Note 20 - Employee Benefit Plan

Note 20 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	20 . Employee Benefit Plan We maintain an employee benefit plan under Section 401 may, not 401 $40,000 $12,000 2018 2017,

Note 21 - Supplemental Disclosu

Note 21 - Supplemental Disclosure for Statements of Cash Flows	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	2 1 . Supplemental Disclosure for Statements of Cash Flows During 2018 2017, $8,000 $7.4 2017, 1 $334,000. 2018 2017, 94,684 105,308 401 $36,000 $54,000, November 2018, $393,000 5.1%. November 2017, $396,000 4.0%. 9, $200,000 January 2017. 15, November 2018, 18.5 16.4 $3.2 $2.2 $1.0

Note 22 - Subsequent Events

Note 22 - Subsequent Events	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	2 2. Subsequent Events On February 11, 2019, February 19, 2019, March 1, 2019 February 20, 2019, may On February 20, 2019, February 20, 2019, March 13, 2019, may not On March 7, 2019, 23.5 15. Except as described above, the Company has evaluated events and transactions subsequent to December 31, 2018 10

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Nature of Operations [Policy Text Block]	a. Organization and Nature of Operations: Navidea’s Manocept platform is predicated on the ability to specifically target the CD206 Tc99m first On March 3, 2017, November 23, 2016, 414 ® November 15, 2007, 414 no Our consolidated balance sheets and statements of operations have been reclassified, as required, for all periods presented to reflect the Business as a discontinued operation. Cash flows associated with the operation of the Business have been combined with operating, investing and financing cash flows, as appropriate, in our consolidated statements of cash flows. Other than Tc99m none In January 2015, In July 2011, Tc99m 100% In December 2001, August 2009, 2013. not September 2017.
Consolidation, Policy [Policy Text Block]	b. Principles of Consolidation:
Use of Estimates, Policy [Policy Text Block]	c. Use of Estimates:
Fair Value of Financial Instruments, Policy [Policy Text Block]	d. Financial Instruments and Fair Value: 1 3 three Level 1 Level 2 not Level 3 A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. In determining the appropriate levels, we perform a detailed analysis of the assets and liabilities whose fair value is measured on a recurring basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no 3. 5. The following methods and assumptions were used to estimate the fair value of each class of financial instruments: ( 1 Cash and cash equivalents , available-for-sale securities, accounts and other receivables, and accounts payable: ( 2 Notes payable: December 31, 2018 2017 December 31, 2018, $316,000, $316,000. December 31, 2017, $2.4 $2.4 5 12. ( 3 Derivative liabilities: $63,000 December 31, 2018 2017 December 31, 2018 2017 5. ( 4 Warrants: March 2017, 414 five 10 1 $1.50 414 $3.3 December 31, 2017. $334,000, 16
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	e. Stock-Based Compensation: December 31, 2018, two 2002 “2002 2014 “2014 2014 may may 12 15 2002 no may Stock options granted under the 2002 2014 one four not ten 90 Stock-based payments to employees and directors, including grants of stock options, are recognized in the consolidated statement of operations based on their estimated fair values. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. Expected volatilities are based on the Company’s historical volatility, which management believes represents the most accurate basis for estimating expected future volatility under the current circumstances. Navidea uses historical data to estimate forfeiture rates. The expected term of stock options granted is based on the vesting period and the contractual life of the options. The risk-free rate is based on the U.S. Treasury yield in effect at the time of the grant. The assumptions used to calculate the fair value of stock option awards granted during the years ended December 31, 2018 2017 2018 2017 Expected volatility 64% - 76% 66% - 79% Weighted-average volatility 69% 75% Expected dividends — — Expected term (in years) 5.5 - 6.0 5.0 - 6.0 Risk-free rate 2.6% - 2.7% 1.8% - 2.1% The portion of the fair value of stock-based awards that is ultimately expected to vest is recognized as compensation expense over either ( 1 2 may not not 6.
Cash and Cash Equivalents, Policy [Policy Text Block]	f. Cash and Cash Equivalents: three
Investment, Policy [Policy Text Block]	g. Available-for-Sale Securities: three
Receivables, Policy [Policy Text Block]	h . Accounts and Other Receivable s : 8.
Property, Plant and Equipment, Policy [Policy Text Block]	i . Property and Equipment: 9.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	j . Intangible Assets: 5 15 no
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	k . Impairment or Disposal of Long-Lived Assets: may not No December 31, 2018 2017.
Lessee, Leases [Policy Text Block]	l . Leases: 14.
Derivatives, Policy [Policy Text Block]	m . Derivative Instruments: not one one not
Revenue Recognition, Policy [Policy Text Block]	n . Revenue Recognition: We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 4.
Research and Development Expense, Policy [Policy Text Block]	o . Research and Development Costs:
Income Tax, Policy [Policy Text Block]	p . Income Taxes: December 31, 2018 2017. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no December 31, 2018 2017 not twelve December 31, 2018, 2015 2018 17.
New Accounting Pronouncements, Policy [Policy Text Block]	q . Recently Adopted Accounting Standards: May 2014, 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09 2014 09 five may 2014 09, 606 2014 09, 2016 08, 2016 10, 2016 12 2016 20, January 1, 2018, 2014 09 $ 700,000 4. In November 2016, No. 2016 18, Statement of Cash Flows – Restricted Cash 2016 18 2016 18 December 15, 2017, 2016 18 2016 18 January 1, 2018. 2016 18 $5.0 December 31, 2017. In January 2017, No. 2017 01, Business Combinations (Topic 805 2017 01 not not not 2017 01 1 2 2017 01 December 15, 2017, 2017 01 No 2017 01. 2017 01 January 1, 2018. 2017 01 not In May 2017, No. 2017 09, Compensation-Stock Compensation (Topic 718 2017 09 1 not not 2 3 2017 09 December 15, 2017. 2017 09. 2017 09 January 1, 2018. 2017 09 not In March 2018, No. 2018 05, Income Taxes (Topic 740 No. 118 2018 05 740 No. 118. 2018 05 740 2018 05 March 2018 not r . Recent ly Issued Accounting Standards : February 2016, No. 2016 02, Leases (Topic 842 2016 02 842 2016 02 December 15, 2018, 2016 02, 2016 02 $ 286,000 In June 2018, No. 2018 07, Compensation—Stock Compensation (Topic 718 2018 07 718 718 2018 07 718 718 not 1 2 606, Revenue from Contracts with Customers 2018 07 December 15, 2018, 2018 07 not In July 2018, No. 2018 09, Codification Improvements 2018 09 2018 09 December 15, 2018 2018 09 not Also in July 2018, No. 2018 10, Codification Improvements to Topic 842, No. 2018 11, Targeted Improvements to Topic 842, 2018 10 842 2016 02, Leases (Topic 842 2018 11 840, Leases 840 840. 2018 10 2018 11 2016 02 December 15, 2018. not 2018 10 2018 11 In August 2018, No. 2018 13, Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement 2018 13 280, 2018 13 1 1 2 2 3 3 4 3 2018 13 1 3 3 3 2 3 2018 13 1 3 2 3 2018 13 December 15, 2019. not 2018 13 may

Note 1 - Organization and Sum_2

Note 1 - Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2018 2017 Expected volatility 64% - 76% 66% - 79% Weighted-average volatility 69% 75% Expected dividends — — Expected term (in years) 5.5 - 6.0 5.0 - 6.0 Risk-free rate 2.6% - 2.7% 1.8% - 2.1%

Note 3 - Discontinued Operati_2

Note 3 - Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	December 31 , 2018 December 31, 2017 Accrued liabilities $ — $ 7,092 Liabilities associated with discontinued operations, current $ — $ 7,092 Years Ended December 31, 2018 2017 Lymphoseek sales revenue $ — $ 2,917,213 Cost of goods sold — 364,192 Gross profit — 2,553,021 Operating expenses: Research and development (1,835 ) 383,446 Selling, general and administrative — 961,873 Total operating expenses (1,835 ) 1,345,319 Income from discontinued operations 1,835 1,207,702 Interest expense — (1,706,491 ) Income (loss) before income taxes 1,835 (498,789 ) (Provision for) benefit from income taxes (385 ) 8,031 Income (loss) from discontinued operations $ 1,450 $ (490,758 )

Note 4 - Revenue From Contrac_2

Note 4 - Revenue From Contracts With Customers (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Year Ended Dec ember 3 1 , 2018 Diagnostics Therapeutics Total Royalty revenue: Europe $ 15,347 $ — $ 15,347 India — — — China — — — Total $ 15,347 $ — $ 15,347 License revenue: NAV4694 sublicense $ 287,569 $ — $ 287,569 Tc99m tilmanocept sublicense, China 19,605 — 19,605 Total $ 307,174 $ — $ 307,174 Other revenue: Additional stability studies $ 15,037 $ — $ 15,037
Contract with Customer, Asset and Liability [Table Text Block]	Year Ended Dec ember 3 1 , 2018 2017 Total deferred revenue, beginning of period $ 26,061 $ 41,098 Impact of adoption of ASU 2014-09 and related standards 700,000 — Revenue deferred related to sublicense 10,000 — Revenue recognized from satisfaction of performance obligations (25,037 ) (15,037 ) Total deferred revenue, end of period $ 711,024 $ 26,061
Accounting Standards Update 2014-09 [Member]
Notes Tables
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Pre- Adoption Post-Adoption Change Deferred revenue $ 26,061 $ 726,061 $ 700,000 Accumulated deficit (319,908,968 ) (320,608,968 ) (700,000 )

Note 5 - Fair Value (Tables)

Note 5 - Fair Value (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Assets and Liabilities Measured at Fair Value on a Recurring Basis as of December 31, 2018 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Certificates of deposit $ — $ 799,270 $ — $ 799,270 Liabilities: Liability related to MT warrants $ — $ — $ 63,000 $ 63,000 Assets and Liabilities Measured at Fair Value on a Recurring Basis as of December 31, 2017 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Assets: Certificates of deposit $ — $ 1,797,604 $ — $ 1,797,604 Liabilities: Liability related to MT warrants $ — $ — $ 63,000 $ 63,000

Note 6 - Stock-based Compensa_2

Note 6 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Year Ended December 31, 201 8 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at beginning of year 3,687,679 $ 1.50 Granted 470,000 0.53 Exercised — — Canceled and forfeited (992,510 ) 1.86 Expired (7,000 ) 0.66 Outstanding at end of year 3,158,169 $ 1.24 6.6 $ — Exercisable at end of year 1,502,173 $ 1.87 4.4 $ —
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Year Ended December 31, 201 8 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of year 150,000 $ 0.51 Granted 200,000 0.37 Forfeited (50,000 ) 0.36 Vested (200,000 ) 0.47 Unvested at end of year 100,000 $ 0.37

Note 7 - (Loss) Earnings Per _2

Note 7 - (Loss) Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	2018 2017 Weighted average shares outstanding, basic 170,535,343 161,592,569 Dilutive shares related to warrants — 4,273,889 Unvested restricted stock — 150,000 Weighted average shares outstanding, diluted 170,535,343 166,016,458

Note 8 - Accounts and Other R_2

Note 8 - Accounts and Other Receivables and Concentrations of Credit Risk (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	201 8 201 7 Guaranteed earnout receivable, current $ — $ 8,084,392 Trade 12,378 — Other 8,773 53,480 Total accounts and other receivables $ 21,151 $ 8,137,872

Note 9 - Property and Equipme_2

Note 9 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	Useful Life (in years) 201 8 201 7 Production machinery and equipment 3 – 5 $ 575,091 $ 575,091 Other machinery and equipment, primarily computers and research equipment 5 323,259 293,757 Furniture and fixtures 7 4,327 4,327 Purchased software 3 336,060 320,435 Leasehold improvements* Term of Lease 12,448 12,448 Total property and equipment $ 1,251,185 $ 1,206,058

Note 11 - Accounts Payable, A_2

Note 11 - Accounts Payable, Accrued Liabilities and Other (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	201 8 201 7 Compensation $ 1,637,337 $ 915,672 Contracted services 866,934 923,115 Other 12,776 19,061 Total accrued liabilities and other $ 2,517,047 $ 1,857,848

Note 13 - Terminated Lease Li_2

Note 13 - Terminated Lease Liability (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Terminated Lease Liability [Table Text Block]	Terminated Lease Liability Total liability, January 1, 2018 $ 695,307 Changes in estimated future payments (43,393 ) Payments under Blazer lease (491,031 ) Receipts from subtenant 391,242 Accretion of liability 37,048 Total liability, December 31, 2018 $ 589,173

Note 14 - Leases (Tables)

Note 14 - Leases (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Operating Leases 2019 $ 339,202 2020 319,034 2021 306,781 2022 253,339 Total future minimum lease payments $ 1,218,356

Note 16 - Equity Instruments (T

Note 16 - Equity Instruments (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Exercise Price Number of Warrants Expiration Date Series HH 2.49 301,205 June 2023 Series KK 1.918 391,032 March 2021 Series LL 0.01 4,365,280 August 2035 Series MM 2.50 150,000 September 2019 Series MM 2.50 150,000 October 2019 Series NN 1.50 11,000,000 March 2022 Total warrants $ 1.15 * 16,357,517

Note 17 - Income Taxes (Tables)

Note 17 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2018 2017 Deferred tax assets: Net operating loss carryforwards $ 29,597,313 $ 29,570,581 R&D credit carryforwards 9,067,874 10,043,714 AMT credit carryforward 621,240 1,229,979 Stock compensation 375,731 576,024 Intangibles 550,797 591,651 Gain/loss from discontinued operations — (2,510,699 ) Disallowed interest expense 878,929 — Temporary differences 480,888 207,447 Deferred tax assets before valuation allowance 41,572,772 39,708,697 Valuation allowance (40,951,532 ) (38,478,718 ) Net deferred tax assets $ 621,240 $ 1,229,979
Summary of Tax Credit Carryforwards [Table Text Block]	As of December 31, 201 8 Generated Expiration U.S. Net Operating Loss Carryforwards U.S. R&D Credit Carryforwards 1999 2019 $ — $ 130,359 2000 2020 — 71,713 2001 2021 — 39,128 2002 2022 — 5,350 2003 2023 — 2,905 2004 2024 — 22,861 2005 2025 — 218,332 2006 2026 — 365,541 2007 2027 — 342,898 2008 2028 — 531,539 2009 2029 — 596,843 2010 2030 — 1,094,449 2011 2031 — 1,950,744 2012 2032 18,684,249 468,008 2013 2033 37,450,522 681,772 2014 2034 34,088,874 816,116 2015 2035 25,073,846 492,732 2016 2036 15,581,209 262,257 2017 2037 — 387,892 2018 2038 — 197,547 Total carryforwards $ 130,878,700 $ 8,678,986
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2018 2017 Amount % Amount % Benefit at statutory rate $ (3,383,491 ) (21.0 )% $ (6,048,423 ) (34.0 )% Adjustments to valuation allowance 2,458,580 15.3 % (26,080,051 ) (146.6 )% Adjustments to R&D credit carryforwards 975,840 6.1 % (291,745 ) (1.6 )% Tax law changes — — 28,731,045 161.5 % Permanent items and other (60,682 ) (0.3 )% (373,315 ) (2.2 )% Benefit per financial statements $ (9,753 ) $ (4,062,489 )

Note 18 - Segments (Tables)

Note 18 - Segments (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Year Ended December 31, 2018 Diagnostics Therapeutics Corporate Total Royalty revenue $ 15,347 $ — $ — $ 15,347 License revenue 307,174 — — 307,174 Grant and other revenue 494,997 351,833 — 846,830 Total revenue 817,518 351,833 — 1,169,351 Cost of revenue 96,636 — — 96,636 Research and development expenses 3,064,115 1,157,766 — 4,221,881 Selling, general and administrative expenses, excluding depreciation and amortization (a) — 78,606 7,469,144 7,547,750 Depreciation and amortization (b) — — 150,385 150,385 Loss from operations (c) (2,343,233 ) (884,539 ) (7,619,529 ) (10,847,301 ) Other expense (d) — — (5,321,270 ) (5,321,270 ) Benefit from income taxes 1,413 534 7,806 9,753 Loss from continuing operations (2,341,820 ) (884,005 ) (12,932,993 ) (16,158,818 ) Income from discontinued operations, net of tax effect 1,449 — — 1,449 Gain on sale of discontinued operations, net of tax effect 43,053 — — 43,053 Net loss (2,297,318 ) (884,005 ) (12,932,993 ) (16,114,316 ) Total assets, net of depreciation and amortization: United States $ 91,425 24,763 6,878,129 6,994,317 International 14,330 381 14,711 Capital expenditures — — 46,192 46,192 Year Ended December 31, 2017 Diagnostics Therapeutics Corporate Total Royalty revenue $ 9,126 $ — $ — $ 9,126 License revenue 100,000 — — 100,000 Grant and other revenue 1,506,232 195,079 — 1,701,311 Total revenue 1,615,358 195,079 — 1,810,437 Cost of revenue 3,651 — — 3,651 Research and development expenses, excluding depreciation and amortization 3,784,255 729,587 — 4,513,842 Selling, general and administrative expenses, excluding depreciation and amortization (a) — 34,484 10,895,301 10,929,785 Depreciation and amortization (b) — — 240,166 240,166 Loss from operations (c) (2,172,548 ) (568,992 ) (11,135,467 ) (13,877,007 ) Other income (expense) (d) — — (3,912,679 ) (3,912,679 ) Benefit from income taxes 496,127 129,936 3,436,426 4,062,489 Loss from continuing operations (1,676,421 ) (439,056 ) (11,611,720 ) (13,727,197 ) Income from discontinued operations, net of tax effect 88,673,053 — — 88,673,053 Net income (loss) 86,996,632 (439,056 ) (11,611,720 ) 74,945,856 Total assets, net of depreciation and amortization: United States $ 13,065,871 $ 49,001 $ 7,634,237 $ 20,749,109 International 30,476 — 1,851 32,327 Capital expenditures — — 33,690 33,690

Note 1 - Organization and Sum_3

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) - USD ($)		Mar. 03, 2017	Mar. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2019	Jan. 01, 2018
Notes Payable, Fair Value Disclosure				$ 316,000	$ 2,400,000
Notes Payable, Current, Total				316,074	2,353,639
Derivative Liability, Total				$ 63,000	63,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	[1]			$ 1.15
Impairment of Long-Lived Assets to be Disposed of				$ 0	0
Unrecognized Tax Benefits, Ending Balance				$ 0	0
Open Tax Year				2015 2016 2017 2018
Deferred Revenue							$ 726,061
Cumulative Effect of New Accounting Principle in Period of Adoption					(700,000)
Accounting Standards Update 2014-09 [Member] | Sayre Pharmaceuticals [Member]
Deferred Revenue							700,000
Cumulative Effect of New Accounting Principle in Period of Adoption							$ 700,000
Accounting Standards Update 2016-18 [Member] | Previously Reported [Member]
Prior Period Reclassification Adjustment				$ 5,000,000
Accounting Standards Update 2016-02 [Member] | Scenario, Forecast [Member]
Operating Lease, Right-of-Use Asset						$ 286,000
Operating Lease, Liability, Total						$ 286,000
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.01
Finite-Lived Intangible Asset, Useful Life				5 years
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.50
Finite-Lived Intangible Asset, Useful Life				15 years
The 2002 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				12,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant				0
The 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized				15,000,000
The 2002 and 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
The 2002 and 2014 Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				1 year
The 2002 and 2014 Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				4 years
Series NN Warrants [Member]
Class of Warrant or Right, Term			5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.50	$ 1.50
Series NN Warrants [Member] | Cardinal Health 414 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			10,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value					$ 3,300,000
Series NN Warrants [Member] | UCSD [Member]
Class of Warrant or Right, Term		5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,000,000	1,000,000		1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 1.50
Class of Warrant or Right, Grants in Period, Estimated Fair Value			$ 334,000		$ 334,000
Navidea Biopharmaceuticals Limited [Member]
Noncontrolling Interest, Ownership Percentage by Parent				100.00%
[1]	Weighted average exercise price.

Note 1 - Organization and Sum_4

Note 1 - Organization and Summary of Significant Accounting Policies - Assumptions Used to Calculate Fair Value of Stock Option Awards Granted (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Expected volatility, minimum	64.00%	66.00%
Expected volatility, maximum	76.00%	79.00%
Weighted-average volatility	69.00%	75.00%
Expected dividends
Risk-free rate	2.60%	1.80%
Risk-free rate	2.70%	2.10%
Minimum [Member]
Expected term (Year)	5 years 182 days	5 years
Maximum [Member]
Expected term (Year)	6 years	6 years

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($)	Nov. 20, 2018	Sep. 13, 2018	Aug. 14, 2018	Sep. 30, 2018	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Mar. 03, 2017
Proceeds from Issuance of Common Stock						$ 3,000,200	$ 72,419
Private Placement [Member]
Stock Issued During Period, Shares, New Issues		18,320,610		18,320,610
Proceeds from Issuance of Common Stock		$ 3,000,000
Former Chief Executive Officer and President [Member]
Severance Costs, Payable			$ 978,000
Severance Costs , Payable Period			2 years
Severance Costs, Payable for Continuation of Healthcare Coverage			$ 35,000
Severance Costs, Payable, Period for Healthcare Coverage			1 year 120 days
Common Stock Shares Provided by Agreement			23,500,000
Stock Issued During Period, Shares, Termination Agreement	18,500,000
Stock Issued During Period, Shares, Termination Agreement, Portion Placed in Escrow	5,000,000
PPCO [Member] | Platinum Loan Agreement [Member]
Convertible Debt, Total								$ 1,900,000
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration					$ 4,100,000	$ 4,100,000

Note 3 - Discontinued Operati_3

Note 3 - Discontinued Operations (Details Textual) - USD ($)	Apr. 09, 2018	Apr. 02, 2018	Mar. 31, 2017	Mar. 03, 2017	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total						$ 43,053	$ 89,163,811
Warrants Issued During Period, Value Issued, Asset Sale							3,337,187
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration					$ 4,100,000	4,100,000
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | Term Loan Agreement [Member]
Repayments of Debt	$ 7,100,000		$ 59,000,000
Sale of Assets to Cardinal Health 414 [Member]
Sale of Assets, Cash Received from Buyer, After Adjustments, Inventory Transferred				$ 80,600,000
Sale of Assets, Cash Received from Buyer, After Adjustments, Advances of Guaranteed Earnout Payments				$ 3,000,000
Sale of Assets, Cash Received from Buyer as Result of Amendment		$ 6,000,000
Sale of Assets, Maximum Amount Receivable from Buyer for Unused Portion of Letter of Credit		$ 7,100,000
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total						43,000	89,200,000
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Guaranteed Consideration						54,000	16,500,000
Warrants Issued During Period, Value Issued, Asset Sale							3,300,000
Sale of Assets, Legal and Other Fees Related to the Sale							2,000,000
Sale of Assets, Net Balance Sheet Dispositions and Write-offs					$ 800,000		800,000
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation						$ 11,000	$ 4,100,000

Note 3 - Discontinued Operati_4

Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Accrued liabilities		$ 7,092
Liabilities associated with discontinued operations, current		7,092
Lymphoseek sales revenue		2,917,213
Cost of goods sold		364,192
Gross profit		2,553,021
Operating expenses of discontinued operation:
Research and development	(1,835)	383,446
Selling, general and administrative		961,873
Total operating expenses	(1,835)	1,345,319
Income from discontinued operations	1,835	1,207,702
Interest expense		(1,706,491)
Income (loss) before income taxes	1,835	(498,789)
(Provision for) benefit from income taxes	(385)	8,031
Income (loss) from discontinued operations	$ 1,449	$ (490,758)

Note 4 - Revenue From Contrac_3

Note 4 - Revenue From Contracts With Customers (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Cumulative Effect of New Accounting Principle in Period of Adoption			$ (700,000)
Revenue from Contract with Customer, Including Assessed Tax	$ 338,000
Contract with Customer, Asset, Impairment Loss	$ 0
Contract with Customer, Payment Term, Minimum	15 days
Contract with Customer, Payment Term, Maximum	90 days
Contract with Customer, Asset, Net, Total	$ 12,000
Contract with Customer, Transaction Price of Royalties Using Expected Value Method	0
Capitalized Contract Cost, Net, Total	$ 0
INDIA
Contract with Customer, Term of Contract	8 years
CHINA
Contract with Customer, Term of Contract	10 years
Long-term Contract with Customer [Member]
Contract with Customer, Performance Obligation Satisfied in Previous Period	$ 0
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption			$ (700,000)
Accounting Standards Update 2014-09 [Member] | Sayre Pharmaceuticals [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption		$ 700,000
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption		(700,000)
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member] | Sayre Pharmaceuticals [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption		(100,000)
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member] | Beijing Sinotau Medical Research Co., Ltd. [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption		$ (600,000)

Note 4 - Revenue From Contrac_4

Note 4 - Revenue From Contracts With Customers - Change in Deferred Revenue and Accumulated Deficit (Details) - USD ($)	Dec. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Deferred revenue		$ 726,061
Accumulated deficit	$ (336,722,905)	(320,608,968)	$ (319,908,968)
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Deferred revenue			26,061
Accumulated deficit			$ (319,908,968)
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Deferred revenue		700,000
Accumulated deficit		$ (700,000)

Note 4 - Revenue From Contrac_5

Note 4 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Revenue from contract with customer	$ 338,000
Royalty [Member]
Revenue from contract with customer	15,347	$ 9,126
Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	15,347	9,126
Royalty [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
NAV4694 Sublicense [Member]
Revenue from contract with customer	287,569
NAV4694 Sublicense [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	287,569
NAV4694 Sublicense [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
License [Member]
Revenue from contract with customer	307,174	100,000
License [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	307,174	100,000
License [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
Product and Service, Other [Member]
Revenue from contract with customer	15,037
Product and Service, Other [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	15,037
Product and Service, Other [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
Europe [Member] | Royalty [Member]
Revenue from contract with customer	15,347
Europe [Member] | Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	15,347
Europe [Member] | Royalty [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
INDIA | Royalty [Member]
Revenue from contract with customer
INDIA | Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer
INDIA | Royalty [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
CHINA | Royalty [Member]
Revenue from contract with customer
CHINA | Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer
CHINA | Royalty [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
CHINA | Expanded Tc99m Tilmanocept License Agreement [Member]
Revenue from contract with customer	19,605
CHINA | Expanded Tc99m Tilmanocept License Agreement [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	19,605
CHINA | Expanded Tc99m Tilmanocept License Agreement [Member] | Therapeutics Segment [Member]
Revenue from contract with customer

Note 4 - Revenue From Contrac_6

Note 4 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Total deferred revenue, beginning of period	$ 26,061	$ 41,098
Impact of adoption of ASU 2014-09 and related standards	700,000
Revenue deferred related to sublicense	10,000
Revenue recognized from satisfaction of performance obligations	(25,037)	(15,037)
Total deferred revenue, end of period	$ 711,024	$ 26,061

Note 5 - Fair Value (Details Te

Note 5 - Fair Value (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018
Derivative Liability, Total	$ 63,000	$ 63,000
Fair Value, Inputs, Level 1 [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total	(153,000)
Other Liabilities [Member]
Derivative Liability, Total	$ 63,000	$ 63,000

Note 5 - Fair Value - Financial

Note 5 - Fair Value - Financial Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)		Dec. 31, 2018	Dec. 31, 2017
Derivative Liability, Total		$ 63,000	$ 63,000
Fair Value, Measurements, Recurring [Member]
Certificates of deposit		799,270	1,797,604
Derivative Liability, Total	[1],[2]	63,000	63,000
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Certificates of deposit
Derivative Liability, Total	[1],[2]
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Certificates of deposit		799,270	1,797,604
Derivative Liability, Total	[1],[2]
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Certificates of deposit
Derivative Liability, Total	[1],[2]	$ 63,000	$ 63,000
[1]	a. Valuation Processes-Level 3 Measurements: The Company utilizes third-party valuation services that use complex models such as Monte Carlo simulation to estimate the value of our financial liabilities.
[2]	b. Sensitivity Analysis-Level 3 Measurements: Changes in the valuation of MT as a whole may cause material changes in the fair value of the MT warrants. Significant increases (decreases) in the valuation of MT, such as may be the result of additional financing, could result in a higher (lower) fair value measurement. A change in the valuation of MT would not necessarily result in a directionally similar change in the value of the MT warrants.

Note 6 - Stock-based Compensa_3

Note 6 - Stock-based Compensation (Details Textual) - USD ($)	1 Months Ended			12 Months Ended
	Aug. 31, 2018	Mar. 31, 2018	Oct. 31, 2017	Dec. 31, 2018	Dec. 31, 2017
Allocated Share-based Compensation Expense, Total				$ 307,000	$ 394,000
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense				$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$ 0.20	$ 0.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period					50,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value					$ 4,400
Stock Issued During Period, Shares, Share-based Compensation, Gross					50,000
Proceeds from Stock Options Exercised					$ 18,100
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				$ 0	$ 0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total				$ 71,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				1 year 73 days
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				200,000	207,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value				$ 59,000	$ 99,000
Restricted Stock [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period					17,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value					$ 9,000
Stock Issued During Period, Shares, Share-based Compensation, Forfeited	50,000		50,000		140,000
Stock Issued During Period, Value, Share-based Compensation, Forfeited	$ 7,000		$ 22,000		$ 65,000
Restricted Stock [Member] | Director [Member] | Vesting Upon Retirement [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 36,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period		100,000
Restricted Stock [Member] | Director [Member] | Vesting As Scheduled [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				$ 23,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period				100,000
Restricted Stock [Member] | Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period					50,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value					$ 25,000

Note 6 - Stock-based Compensa_4

Note 6 - Stock-based Compensation - Summary of Stock Option Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Outstanding at beginning of year (in shares)	3,687,679
Outstanding at beginning of year, weighted average exercise price (in dollars per share)	$ 1.50
Granted (in shares)	470,000
Granted, weighted average exercise price (in dollars per share)	$ 0.53
Exercised (in shares)		(50,000)
Exercised, weighted average exercise price (in dollars per share)
Canceled and forfeited (in shares)	(992,510)
Canceled and Forfeited, weighted average exercise price (in dollars per share)	$ 1.86
Expired (in shares)	(7,000)
Expired (in dollars per share)	$ 0.66
Outstanding at end of year (in shares)	3,158,169	3,687,679
Outstanding at end of year, weighted average exercise price (in dollars per share)	$ 1.24	$ 1.50
Outstanding at end of year, weighted average remaining contractual life (Year)	6 years 219 days
Outstanding at end of year, aggregate intrinsic value
Exercisable at end of year (in shares)	1,502,173
Exercisable at end of year, weighted average exercise price (in dollars per share)	$ 1.87
Exercisable at end of year, weighted average remaining contractual life (Year)	4 years 146 days
Exercisable at end of year, aggregate intrinsic value

Note 6 - Stock-based Compensa_5

Note 6 - Stock-based Compensation - Summary of Unvested Restricted Stock (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Unvested at beginning of year (in shares)	150,000
Unvested at beginning of year, weighted average grant-date fair value (in dollars per share)	$ 0.51
Granted (in shares)	200,000
Granted, weighted average grant-date fair value (in dollars per share)	$ 0.37
Forfeited (in shares)	(50,000)
Forfeited, weighted average grant-date fair value (in dollars per share)	$ 0.36
Vested (in shares)	(200,000)	(207,000)
Vested, weighted average grant-date fair value (in dollars per share)	$ 0.47
Unvested at end of year (in shares)	100,000	150,000
Unvested at end of year, weighted average grant-date fair value (in dollars per share)	$ 0.37	$ 0.51

Note 7 - (Loss) Earnings Per _3

Note 7 - (Loss) Earnings Per Share (Details Textual) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Stock Options, Warrants, Convertible Debt, and Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	17,900,000	14,500,000
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	100,000	150,000

Note 7 - (Loss) Earnings Per _4

Note 7 - (Loss) Earnings Per Share - Earnings (Loss) Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Weighted average shares outstanding, basic (in shares)	170,535,343	161,592,569
Dilutive shares related to warrants (in shares)		4,273,889
Unvested restricted stock (in shares)		150,000
Weighted average shares outstanding, diluted (in shares)	170,535,343	166,016,458

Note 8 - Accounts and Other R_3

Note 8 - Accounts and Other Receivables and Concentrations of Credit Risk (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Allowance for Doubtful Accounts Receivable, Current, Ending Balance	$ 0	$ 0
Customer Concentration Risk [Member] | Accounts and Other Receivables [Member] | Meilleur [Member]
Concentration Risk, Percentage	47.00%
Customer Concentration Risk [Member] | Accounts and Other Receivables [Member] | Cardinal Health 414 [Member]
Concentration Risk, Percentage		99.00%

Note 8 - Accounts and Other R_4

Note 8 - Accounts and Other Receivables and Concentrations of Credit Risk - Accounts and Other Receivables (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Accounts and other receivables	$ 21,151	$ 8,137,872
Guaranteed Earnout Receivable, Current [Member]
Accounts and other receivables		8,084,392
Trade Accounts Receivable [Member]
Accounts and other receivables	12,378
Other Accounts Receivable [Member]
Accounts and other receivables	$ 8,773	$ 53,480

Note 9 - Property and Equipme_3

Note 9 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment, Gross, Ending Balance	$ 1,251,185	$ 1,206,058
Depreciation, Depletion and Amortization, Total	120,721	232,339
Assets Held under Capital Leases [Member]
Property, Plant and Equipment, Gross, Ending Balance	$ 0	$ 0

Note 9 - Property and Equipme_4

Note 9 - Property and Equipment - Summary of Major Classes of Property and Equipment (Details) - USD ($)		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment, Gross, Ending Balance		$ 1,251,185	$ 1,206,058
Machinery and Equipment [Member]
Property, Plant and Equipment, Gross, Ending Balance		$ 575,091	575,091
Machinery and Equipment [Member] | Minimum [Member]
Property and Equipment, Useful Life (Year)		3 years
Machinery and Equipment [Member] | Maximum [Member]
Property and Equipment, Useful Life (Year)		5 years
Other Machinery and Equipment [Member]
Property and Equipment, Useful Life (Year)		5 years
Property, Plant and Equipment, Gross, Ending Balance		$ 323,259	293,757
Furniture and Fixtures [Member]
Property and Equipment, Useful Life (Year)		7 years
Property, Plant and Equipment, Gross, Ending Balance		$ 4,327	4,327
Purchased Software [Member]
Property and Equipment, Useful Life (Year)		3 years
Property, Plant and Equipment, Gross, Ending Balance		$ 336,060	320,435
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross, Ending Balance	[1]	$ 12,448	$ 12,448
Property and Equipment, Useful Life	[1]	Term of Lease
[1]	We amortize leasehold improvements over the term of the lease, which in all cases is shorter than the estimated useful life of the asset.

Note 10 - Investment in Macro_2

Note 10 - Investment in Macrophage Therapeutics, Inc. (Details Textual) - USD ($)	Mar. 07, 2019	Mar. 11, 2015	Jan. 31, 2017	Jul. 31, 2016	May 31, 2016	Mar. 31, 2015	Dec. 31, 2017	Dec. 31, 2015	Dec. 31, 2018	Aug. 31, 2018
Preferred Stock, Shares Authorized							5,000,000		5,000,000
Preferred Stock, Par or Stated Value Per Share							$ 0.001		$ 0.001
Preferred Stock, Shares Issued, Total							0		0
Derivative Liability, Total							$ 63,000		$ 63,000
Preferred Convertible Stock, Right to Exchange for Common Shares, Minimum Required Proceeds from Initial Public Offering								$ 50,000,000
Weighted Average Price Common Stock Percentage								80.00%
Future Common Stock Conversion Share Price								3.00%
Reclassification of Funds Invested			$ 200,000				200,000
Subsequent Event [Member] | Complaint By Dr. Goldberg Against Navidea and MT [Member] | MT [Member]
Litigation Case, Number of Shares of Super Voting Common Stock Failed to Issue	23,500,000
Common Stock [Member]
Reclassification of Funds Invested
Dr. Michael Goldberg [Member]
Convertible Preferred Stock, Percent of Shares Reserved						40.00%
Dr. Michael Goldberg [Member] | MT [Member]
Payments to Acquire Businesses and Interest in Affiliates, Total				$ 200,000
Resignation Agreement, Percentage Ownership After Signing										5.00%
Macrophage Therapeutics [Member]
Common Stock Shares Authorized Upon Exercise of Warrants						1,500
Convertible Preferred Stock Shares Issued Upon Conversion, Per Unit						1
Common Stock Warrants, Issued Upon Conversion, Per Unit						30
Macrophage Therapeutics [Member] | Common Stock [Member]
Common Stock as Percentage of Common Equity						1.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		300							300
Platinum [Member] | MT [Member]
Payments to Acquire Businesses and Interest in Affiliates, Total				$ 300,000	$ 200,000
MT [Member]
Convertible Preferred Stock, PIK Coupon, Percentage				10.00%
Convertible Preferred Stock, Conversion Price, Market Cap				$ 500,000,000
Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized						50
Preferred Stock, Par or Stated Value Per Share						$ 50,000
Cumulative Preferred Stock [Member]
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants, Total		$ 500,000
Issuance of Stock and Warrants for Purchase Agreement, Remaining Amount								$ 2,000,000
Preferred Stock, Fair Value Put Option								113,000
Future Common Stock Conversion Denominator, Value								$ 50,000
Cumulative Preferred Stock [Member] | Macrophage Therapeutics [Member]
Preferred Stock, Shares Authorized						50
Preferred Stock, Shares Issued, Total						10
Preferred Stock, Redemption Price Per Share								$ 58,320

Note 11 - Accounts Payable, A_3

Note 11 - Accounts Payable, Accrued Liabilities and Other (Details Textual) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Executive Bonuses, Director Fees, Deferred Salary, and Scientific Advisory Board Fees [Member] | Accrued Liabilities and Other [Member]
Due to Related Parties, Current, Total	$ 1,600,000	$ 975,000
Former Executive [Member]
Accounts Payable, Disputed		$ 96,000

Note 11 - Accounts Payable, A_4

Note 11 - Accounts Payable, Accrued Liabilities and Other - Accrued Liabilities and Other (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Compensation	$ 1,637,337	$ 915,672
Contracted services	866,934	923,115
Other	12,776	19,061
Total accrued liabilities and other	$ 2,517,047	$ 1,857,848

Note 12 - Notes Payable (Detail

Note 12 - Notes Payable (Details Textual)	Apr. 09, 2018USD ($)	Mar. 31, 2017USD ($)	Mar. 03, 2017USD ($)	Jul. 01, 2016	Jun. 22, 2016USD ($)	Mar. 31, 2014	Nov. 30, 2018USD ($)	Dec. 31, 2017USD ($)	Nov. 30, 2017USD ($)	May 31, 2015USD ($)$ / shares	Mar. 31, 2014	Jun. 30, 2013USD ($)shares	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Jun. 25, 2013USD ($)	Jul. 31, 2012USD ($)
Repayments of Notes Payable													$ 395,573	$ 59,753,740
Interest Expense, Debt, Total													161,000	159,000
Notes Payable, Current, Total								$ 2,353,639					316,074	2,353,639
Interest Expense Recorded Related to Amortization of Debt Discounts and Deferred Financing Costs													153,000	134,000
Disposal Group, Including Discontinued Operation, Interest Expense														1,706,491
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months													316,000
CRG [Member]
Draws on Letter of Credit	$ 7,100,000
Judicial Ruling [Member] | CRG Loan Agreement, Texas Case [Member]
Loss Contingency, Damages Awarded, Value, Additional Amount			$ 7,000,000					7,000,000
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration								4,100,000					4,100,000
Maximum [Member] | Judicial Ruling [Member] | CRG Loan Agreement, Texas Case [Member]
Loss Contingency, Damages Awarded, Value			66,000,000					66,000,000
Platinum Loan Agreement [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability								0					0	0
Convertible Debt, Fair Value Disclosures								2,000,000					0	2,000,000
Platinum Loan Agreement [Member] | PPCO [Member]
Line of Credit Facility, Maximum Borrowing Capacity																		$ 50,000,000
Line of Credit Facility, Current Borrowing Capacity																		35,000,000
Line of Credit Facility, Increase Additional Borrowings Terms Not Negotiated																		$ 15,000,000
Proceeds from Lines of Credit, Total																	$ 8,000,000
Repayments of Debt			7,700,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total													0	(153,000)
Platinum-Montaur Life Sciences LLC Litigation [Member]
Line of Credit Facility, Current Borrowing Capacity												$ 35,000,000
Debt Instrument, Interest Rate, Stated Percentage						10.00%				10.00%	10.00%	10.00%
InterestRateInAdditionToAmendedAgreement												0.125%
Repayments of Notes Payable												$ 4,800,000
Stock for Stock Conversion Number of Shares Converted | shares												2,364.9
Number of Common Shares Underlying Series B Preferred Stock | shares												7,733,223
Shares Conversion, Number of Common Stock Equivalent to Each Preferred Stock | shares												3,270
Debt Instrument, Convertible, Threshold Trading Days										10
Debt Instrument, Convertible, Stock Price Trigger | $ / shares										$ 2.53
Line of Credit Facility, Decrease Forgiveness Interest Percentage				6.00%
Interest Expense, Debt, Excluding Amortization													153,000	265,000
Platinum-Montaur Life Sciences LLC Litigation [Member] | Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate										6.75%	6.75%	6.75%
Platinum-Montaur Life Sciences LLC Litigation [Member] | Oxford Financing Rate [Member]
Debt Instrument, Basis Spread on Variable Rate						0.125%
Platinum-Montaur Life Sciences LLC Litigation [Member] | Interest Rate Pursuant to CRG Term Loan [Member]
Debt Instrument, Basis Spread on Variable Rate										0.125%
Term Loan Agreement [Member] | Judicial Ruling [Member] | CRG Loan Agreement, Texas Case [Member]
Repayments of Debt	$ 7,100,000	$ 59,000,000
Term Loan Agreement [Member] | CRG [Member]
Debt Instrument, Interest Rate, Stated Percentage										14.00%
Interest Expense, Debt, Excluding Amortization															$ 1,800,000	$ 1,800,000
Repayments of Debt			59,000,000
Debt Instrument, Face Amount										$ 50,000,000
Debt Instrument, Additional Loans That May Be Made Available Upon the Satisfaction of Certain Conditions										$ 10,000,000
Percentage of Per Annum Interest Paying in Cash										10.00%
Percentage of Per Annum Interest as Compounded Interest										4.00%
Debt Instrument, Number of Quarterly Payments										8
Debt Instrument Payment Terms Payment Period										2 years
Debt Instrument, Covenant Compliance, Income (Loss) Earnings Before Interest, Taxes, Depreciation, and Amortization, Minimum										$ 5,000,000
Debt Instrument, Covenant Compliance Sales Revenue Minimum Next Twelve Months															$ 22,500,000
DebtInstrumentCovenantComplianceTargetRevenueMinimum										$ 45,000,000
Debt Instrument, Covenant Compliance Cure Right Ratio										2.5
Debt Instrument, Covenant Compliance Liquidity Minimum										$ 5,000,000
Debt Instrument, Interest Rate in the Event of Default										18.00%
Primary Bank Account Cash Taken Possession Of By Creditor					$ 4,100,000
Payments to Prepayment Premium and Backend Facility Fee on Claims of Default					3,900,000
Payments to Principal Balance of Debt on Claims of Default					$ 189,000
Term Loan Agreement [Member] | CRG [Member] | Judicial Ruling [Member] | CRG Loan Agreement, Texas Case [Member]
Repayments of Debt		$ 59,000,000	59,000,000
Term Loan Agreement [Member] | CRG [Member] | Maximum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount			$ 66,000,000					66,000,000						66,000,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member]
Notes Payable, Current, Total								$ 318,000					316,000	318,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | IPFS [Member]
Debt Instrument, Interest Rate, Stated Percentage							5.10%		4.00%
Debt Instrument, Face Amount							$ 393,000		$ 396,000
Debt Instrument, Term							300 days		300 days
Debt Instrument, Periodic Payment, Total							$ 40,000		$ 40,000
Interest Expense, Debt, Total													$ 8,000	$ 12,000

Note 13 - Terminated Lease Li_3

Note 13 - Terminated Lease Liability (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Jun. 01, 2017
Gain (Loss) on Contract Termination	$ (399,000)
Lease Termination of Blazer [Member]
Terminated Lease Liability	695,307	$ 589,173	$ 1,000,000
Lease Termination of Blazer [Member] | Selling, General and Administrative Expenses [Member]
Gain (Loss) on Disposition of Assets, Total	$ (706,000)

Note 13 - Terminated Lease Li_4

Note 13 - Terminated Lease Liability - Summary of Changes in Terminated Lease Liability (Details) - Lease Termination of Blazer [Member]	12 Months Ended
	Dec. 31, 2018USD ($)
Total liability, January 1, 2018	$ 695,307
Changes in estimated future payments	(43,393)
Payments under Blazer lease	(491,031)
Receipts from subtenant	391,242
Accretion of liability	37,048
Total liability, December 31, 2018	$ 589,173

Note 14 - Leases (Details Textu

Note 14 - Leases (Details Textual)	1 Months Ended	12 Months Ended
	Jun. 30, 2017USD ($)	Dec. 31, 2018USD ($)ft²	Dec. 31, 2017USD ($)
Operating Leases, Rent Expense, Net, Total		$ 68,000	$ 139,000
Office Space at 4995 Bradenton Avenue, Dublin Ohio [Member]
Area of Real Estate Property | ft²		5,000
Operating Lease, Monthly Base Rent		$ 3,000
Office Space at 560 Sylvan Avenue, Englewood Cliffs, New Jersey [Member]
Area of Real Estate Property | ft²		2,000
Operating Lease, Monthly Base Rent		$ 3,000
Office Space at 5600 Blazer Parkway, Dublin, Ohio [Member]
Area of Real Estate Property | ft²		25,000
Operating Lease, Monthly Base Rent		$ 26,000
Operating Lease, Sublease, Monthly Rent Revenue	$ 39,000
Vehicle Lease [Member]
Operating Lease, Monthly Base Rent		$ 300

Note 14 - Leases - Summary of F

Note 14 - Leases - Summary of Future Minimum Lease Payments (Details)	Dec. 31, 2018USD ($)
2019	$ 339,202
2020	319,034
2021	306,781
2022	253,339
Total future minimum lease payments	$ 1,218,356

Note 15 - Commitments and Con_2

Note 15 - Commitments and Contingencies (Details Textual)

Mar. 07, 2019shares

Nov. 20, 2018shares

Aug. 14, 2018USD ($)shares

Apr. 12, 2018USD ($)

Apr. 09, 2018USD ($)

Mar. 26, 2018USD ($)

Jan. 16, 2018USD ($)

Nov. 02, 2017USD ($)

May 12, 2017USD ($)

Mar. 31, 2017USD ($)

Mar. 03, 2017USD ($)$ / shares

Oct. 11, 2016USD ($)

Jun. 22, 2016USD ($)

Nov. 30, 2018shares

Dec. 31, 2017USD ($)$ / shares

Jun. 30, 2017USD ($)

Dec. 31, 2018USD ($)$ / sharesshares

Dec. 31, 2019

Jun. 30, 2018USD ($)

Mar. 07, 2017USD ($)

May 31, 2015

Stockholders' Equity Attributable to Parent, Ending Balance

$ 11,379,630

$ 1,742,139

$ 2,100,000

Common Stock, Par or Stated Value Per Share | $ / shares

$ 0.001

$ 0.001

$ 0.001

Common Stock [Member]

Stock Issued During Period, Shares, New Issues | shares

18,320,610

Former Chief Executive Officer and President [Member]

Severance Costs, Payable

$ 978,000

Severance Costs , Payable Period

2 years

Severance Costs, Payable for Continuation of Healthcare Coverage

$ 35,000

Severance Costs, Payable, Period for Healthcare Coverage

1 year 120 days

Common Stock Shares Provided by Agreement | shares

23,500,000

Common Stock Shares Provided by Agreement, Escrow Period

1 year 180 days

Former Chief Executive Officer and President [Member] | Common Stock [Member]

Stock Issued During Period, Shares, New Issues | shares

18,500,000

18,500,000

Stock Issued During Period, Shares, New Issues Placed in Escrow | shares

5,000,000

5,000,000

5,000,000

CRG [Member]

Draws on Letter of Credit

$ 7,100,000

CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Loss Contingency, Damages Awarded, Value, Additional Amount

$ 7,000,000

$ 7,000,000

Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration

4,100,000

$ 4,100,000

CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | Surety Bond [Member]

Loss Contingency, Amount Awarded to Other Party

$ 7,700,000

CRG Loan Agreement, Texas Case [Member] | Pending Litigation [Member]

Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration

$ 4,100,000

Loss Contingency, Damages Awarded,Value, Requested Modified Amount

$ 2,900,000

CRG Loan Agreement, Ohio Case [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 4,100,000

Former CEO Arbitration [Member]

Litigation Settlement, Salary, Bonus, and Benefits, Amount Awarded to Other Party

$ 481,039

Litigation Settlement, Amount Awarded to Other Party

$ 617,880

FTI Consulting, Inc. Litigation [Member] | Pending Litigation [Member] | Investigative and Consulting Services [Member]

Loss Contingency, Damages Sought, Value

$ 730,264

$ 862,165

Litigation Settlement, Amount Awarded to Other Party

$ 435,000

Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 1,900,000

Complaint By Dr. Goldberg Against Navidea and MT [Member] | MT [Member] | Subsequent Event [Member]

Litigation Case, Number of Shares of Super Voting Common Stock Failed to Issue | shares

23,500,000

Dr. Michael Goldberg [Member] | Former Chief Executive Officer and President [Member] | MT [Member] | Common Stock [Member] | Scenario, Forecast [Member]

Ownership Percentage

5.00%

Minimum [Member] | Scenario, Forecast [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

5

Minimum [Member] | FTI Consulting, Inc. Litigation [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

782,600

Minimum [Member] | FTI Consulting, Inc. Litigation [Member] | Pending Litigation [Member] | Purported Interest Due on Unpaid Invoices, Plus Attorneys' Fees, Costs and Expenses [Member]

Loss Contingency, Damages Sought, Value

$ 52,337

Maximum [Member] | Scenario, Forecast [Member]

Stockholders' Equity Note, Stock Split, Conversion Ratio

20

Maximum [Member] | CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Loss Contingency, Damages Awarded, Value

66,000,000

66,000,000

Term Loan Agreement [Member] | CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Repayments of Debt

$ 7,100,000

$ 59,000,000

Term Loan Agreement [Member] | Cardinal Health 414 [Member]

Letters of Credit Outstanding, Amount

7,000,000

Term Loan Agreement [Member] | CRG [Member]

Letters of Credit Outstanding, Amount

12,000,000

$ 12,000,000

Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit

59,000,000

CRG [Member] | Term Loan Agreement [Member]

Debt Instrument, Interest Rate, Stated Percentage

14.00%

Debt Instrument, Interest Rate in the Event of Default

18.00%

Primary Bank Account Cash Taken Possession Of By Creditor

$ 4,100,000

Repayments of Debt

59,000,000

CRG [Member] | Term Loan Agreement [Member] | CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]

Repayments of Debt

$ 59,000,000

59,000,000

CRG [Member] | Term Loan Agreement [Member] | Minimum [Member]

Debt Instrument, Agreed-upon Final Payoff Amount

47,000,000

CRG [Member] | Term Loan Agreement [Member] | Maximum [Member]

Debt Instrument, Agreed-upon Final Payoff Amount

$ 66,000,000

$ 66,000,000

Note 16 - Equity Instruments (D

Note 16 - Equity Instruments (Details Textual)		Nov. 20, 2018shares	Sep. 13, 2018shares	Mar. 03, 2017$ / sharesshares	Nov. 30, 2018shares	Sep. 30, 2018USD ($)$ / sharesshares	Mar. 31, 2017USD ($)$ / sharesshares	Jan. 31, 2017USD ($)shares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Mar. 11, 2015shares
Common Stock, Par or Stated Value Per Share | $ / shares				$ 0.001					$ 0.001	$ 0.001
Stock Issued During Period, Value, New Issues | $									$ 3,000,000
Stock Issued During Period, Value, Issued for Services | $										$ 10,500
Stock Issued During Period, Shares, Employee Benefit Plan									94,684	105,308
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution | $									$ 35,980	$ 53,707
Class of Warrant or Right, Outstanding									16,357,517
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	[1]								$ 1.15
Common Stock, Capital Shares Reserved for Future Issuance									19,515,686
Series NN Warrants [Member]
Class of Warrant or Right, Outstanding									11,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares							$ 1.50		$ 1.50
Class of Warrant or Right, Term							5 years
Series NN Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input							0.77
Series NN Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input							0.02
Series NN Warrants [Member] | Cardinal Health 414 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights							10,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value | $										$ 3,300,000
Series NN Warrants [Member] | UCSD [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 1.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				1,000,000			1,000,000			1,000,000
Class of Warrant or Right, Term				5 years
Class of Warrant or Right, Grants in Period, Estimated Fair Value | $							$ 334,000			$ 334,000
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares									$ 0.01
Warrants and Rights Outstanding, Term									255 days
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares									$ 2.50
Warrants and Rights Outstanding, Term									16 years 219 days
Weighted Average [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares									$ 1.15
Common Stock [Member]
Stock Issued During Period, Shares, New Issues									18,320,610
Stock Issued During Period, Value, New Issues | $									$ 18,321
Stock Issued During Period, Shares, Issued for Services										16,406
Stock Issued During Period, Value, Issued for Services | $										$ 17
Stock Issued During Period, Shares, Employee Benefit Plan									94,684	105,308
Stock Issued During Period, Shares, Issued for Exercise of Warrants										5,411,850
Common Stock [Member] | Macrophage Therapeutics [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares									$ 2,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights									300		300
Common Stock [Member] | Employees [Member]
Stock Issued During Period, Shares, Issued for Services									1,118,760	710,353
Stock Issued During Period, Value, Issued for Services | $									$ 317,000	$ 369,000
Common Stock [Member] | Director [Member]
Stock Issued During Period, Shares, Issued for Services									0	16,406
Stock Issued During Period, Value, Issued for Services | $										$ 10,500
Former Chief Executive Officer and President [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues		18,500,000			18,500,000
Stock Issued During Period, Shares, New Issues Placed in Escrow		5,000,000			5,000,000				5,000,000
Chief Executive Officer [Member]
Class of Warrant or Right, Exercises in Period								5,411,850
Stock Issued During Period, Shares, Issued for Exercise of Warrants								5,411,850
Proceeds from Warrant Exercises | $								$ 54,119
Private Placement [Member]
Stock Issued During Period, Shares, New Issues			18,320,610			18,320,610
Common Stock, Par or Stated Value Per Share | $ / shares						$ 0.001
Stock Issued During Period, Value, New Issues | $						$ 3,000,000
[1]	Weighted average exercise price.

Note 16 - Equity Instruments -

Note 16 - Equity Instruments - Outstanding Warrants (Details) - $ / shares		12 Months Ended
		Dec. 31, 2018	Mar. 31, 2017
Exercise Price (in dollars per share)	[1]	$ 1.15
Number of Warrants (in shares)		16,357,517
Series HH Warrants [Member]
Exercise Price (in dollars per share)		$ 2.49
Number of Warrants (in shares)		301,205
Expiration Date		Jun. 25, 2023
Series KK Warrants [Member]
Exercise Price (in dollars per share)		$ 1.918
Number of Warrants (in shares)		391,032
Expiration Date		Mar. 4, 2021
Series LL Warrants [Member]
Exercise Price (in dollars per share)		$ 0.01
Number of Warrants (in shares)		4,365,280
Expiration Date		Aug. 31, 2035
Series MM Warrants Expire September 2019 [Member]
Exercise Price (in dollars per share)		$ 2.50
Number of Warrants (in shares)		150,000
Expiration Date		Sep. 30, 2019
Series MM Warrants Expire October 2019 [Member]
Exercise Price (in dollars per share)		$ 2.50
Number of Warrants (in shares)		150,000
Expiration Date		Oct. 31, 2019
Series NN Warrants [Member]
Exercise Price (in dollars per share)		$ 1.50	$ 1.50
Number of Warrants (in shares)		11,000,000
[1]	Weighted average exercise price.

Note 17 - Income Taxes (Details

Note 17 - Income Taxes (Details Textual) - USD ($)	Dec. 22, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Deferred Tax Assets, Gross, Total		$ 41,572,772	$ 39,708,697
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	35.00%	21.00%	34.00%
Revaluation of Deferred Tax Asset, Decrease			$ 26,400,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount			26,400,000
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax		$ 621,240	1,229,979
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax, Percentage Reclassified to Income Tax Receivable		50.00%
Cardiosonix [Member] | Subsidiaries [Member]
Net Income (Loss) Attributable to Parent, Total			(5,000)
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total		$ 130,878,700	131,800,000
Operating Loss Carryforwards Stock-based Compensation				$ 15,100,000
Net Operating Loss Carryforwards Expired in Period		0	0
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount		8,678,986	9,700,000
Tax Credit Carryforward, Amount Expired During Period		1,200,000	0
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total		$ 20,300,000	20,400,000
Foreign Tax Authority [Member] | Israel Tax Authority [Member] | Cardiosonix [Member] | Subsidiaries [Member]
Operating Loss Carryforwards, Total				$ 7,700,000
Other Noncurrent Assets [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax			$ 1,200,000

Note 17 - Income Taxes - Compon

Note 17 - Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred tax assets:
Net operating loss carryforwards	$ 29,597,313	$ 29,570,581
R&D credit carryforwards	9,067,874	10,043,714
AMT credit carryforward	621,240	1,229,979
Stock compensation	375,731	576,024
Intangibles	550,797	591,651
Gain/loss from discontinued operations		(2,510,699)
Disallowed interest expense	878,929
Temporary differences	480,888	207,447
Deferred tax assets before valuation allowance	41,572,772	39,708,697
Valuation allowance	(40,951,532)	(38,478,718)
Net deferred tax assets	$ 621,240	$ 1,229,979

Note 17 - Income Taxes - Net Op

Note 17 - Income Taxes - Net Operating Loss and Credit Carryforwards (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 130,878,700	$ 131,800,000
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 8,678,986	$ 9,700,000
Tax Year 1999 [Member]
Expiration dates	Dec. 31, 2019
Tax Year 1999 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 1999 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 130,359
Tax Year 2000 [Member]
Expiration dates	Dec. 31, 2020
Tax Year 2000 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 2000 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 71,713
Tax Year 2001 [Member]
Expiration dates	Dec. 31, 2021
Tax Year 2001 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 2001 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 39,128
Tax Year 2002 [Member]
Expiration dates	Dec. 31, 2022
Tax Year 2002 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 2002 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 5,350
Tax Year 2003 [Member]
Expiration dates	Dec. 31, 2023
Tax Year 2003 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 2003 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 2,905
Tax Year 2004 [Member]
Expiration dates	Dec. 31, 2024
Tax Year 2004 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 2004 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 22,861
Tax Year 2005 [Member]
Expiration dates	Dec. 31, 2025
Tax Year 2005 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 2005 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 218,332
Tax Year 2006 [Member]
Expiration dates	Dec. 31, 2026
Tax Year 2006 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 2006 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 365,541
Tax Year 2007 [Member]
Expiration dates	Dec. 31, 2027
Tax Year 2007 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 2007 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 342,898
Tax Year 2008 [Member]
Expiration dates	Dec. 31, 2028
Tax Year 2008 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 2008 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 531,539
Tax Year 2009 [Member]
Expiration dates	Dec. 31, 2029
Tax Year 2009 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 2009 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 596,843
Tax Year 2010 [Member]
Expiration dates	Dec. 31, 2030
Tax Year 2010 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 2010 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 1,094,449
Tax Year 2011 [Member]
Expiration dates	Dec. 31, 2031
Tax Year 2011 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 2011 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 1,950,744
Tax Year 2012 [Member]
Expiration dates	Dec. 31, 2032
Tax Year 2012 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 18,684,249
Tax Year 2012 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 468,008
Tax Year 2013 [Member]
Expiration dates	Dec. 31, 2033
Tax Year 2013 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 37,450,522
Tax Year 2013 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 681,772
Tax Year 2014 [Member]
Expiration dates	Dec. 31, 2034
Tax Year 2014 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 34,088,874
Tax Year 2014 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 816,116
Tax Year 2015 [Member]
Expiration dates	Dec. 31, 2035
Tax Year 2015 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 25,073,846
Tax Year 2015 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 492,732
Tax Year 2016 [Member]
Expiration dates	Dec. 31, 2036
Tax Year 2016 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards	$ 15,581,209
Tax Year 2016 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 262,257
Tax Year 2017 [Member]
Expiration dates	Dec. 31, 2037
Tax Year 2017 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 2017 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 387,892
Tax Year 2018 [Member]
Expiration dates	Dec. 31, 2038
Tax Year 2018 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
U.S. Net Operating Loss Carryforwards
Tax Year 2018 [Member] | Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
U.S. R&D Credit Carryforwards	$ 197,547

Note 17 - Income Taxes - Reconc

Note 17 - Income Taxes - Reconciliations Between the Statutory Federal Income Tax Rate and the Effective Tax Rate (Details) - USD ($)	Dec. 22, 2017	Dec. 31, 2018	Dec. 31, 2017
Benefit at statutory rate, amount		$ (3,383,491)	$ (6,048,423)
Benefit at statutory rate, percent	(35.00%)	(21.00%)	(34.00%)
Adjustments to valuation allowance, amount		$ 2,458,580	$ (26,080,051)
Adjustments to valuation allowance, percent		15.30%	(146.60%)
Adjustments to R&D credit carryforwards, amount		$ 975,840	$ (291,745)
Adjustments to R&D credit carryforwards, percent		6.10%	(1.60%)
Tax law changes, amount			$ 28,731,045
Tax law changes, percent			161.50%
Permanent items and other, amount		$ (60,682)	$ (373,315)
Permanent items and other, percent		(0.30%)	(2.20%)
Benefit per financial statements		$ (9,753)	$ (4,062,489)

Note 18 - Segments (Details Tex

Note 18 - Segments (Details Textual)		12 Months Ended
		Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Revenues, Total		$ 1,169,351	$ 1,810,437
Number of Primary Types of Products Sold		2
Depreciation, Depletion and Amortization, Nonproduction, Total	[1]	$ 150,385	240,166
Selling, General and Administrative Expenses [Member]
Depreciation, Depletion and Amortization, Nonproduction, Total		150,385	$ 240,166
Intersegment Eliminations [Member]
Revenues, Total		$ 0
[1]	Depreciation and amortization is reflected in selling, general and administrative expenses ($150,385 and $240,166 for the years ended December 31, 2018 and 2017, respectively).

Note 18 - Segments - Segment In

Note 18 - Segments - Segment Information (Details) - USD ($)		12 Months Ended
		Dec. 31, 2018	Dec. 31, 2017
Revenue from contract with customer		$ 338,000
Grant and other revenue		846,830	$ 1,701,311
Revenue		1,169,351	1,810,437
Cost of revenue		96,636	3,651
Research and development expenses		4,221,881	4,513,842
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	7,547,750	10,929,785
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	150,385	240,166
Loss from operations	[3]	(10,847,301)	(13,877,007)
Other income (expense)	[4]	(5,321,270)	(3,912,679)
Benefit from income taxes		9,753	4,062,489
Loss from continuing operations		(16,158,818)	(13,727,197)
Income from discontinued operations, net of tax effect		1,449	88,673,053
Gain on sale of discontinued operations, net of tax effect		43,053	89,163,811
Net income (loss)		(16,114,316)	74,945,856
Total assets, net of depreciation and amortization		7,021,527	20,781,436
Capital expenditures		46,192	33,690
Other income (expense)	[4]	(5,321,270)	(3,912,679)
Benefit from income taxes		9,753	4,062,489
Net income (loss)		(16,114,316)	74,945,856
UNITED STATES
Total assets, net of depreciation and amortization		6,994,317	20,749,109
Non-US [Member]
Total assets, net of depreciation and amortization		14,711	32,327
Royalty [Member]
Revenue from contract with customer		15,347	9,126
License [Member]
Revenue from contract with customer		307,174	100,000
Diagnostics Segment [Member]
Grant and other revenue		494,997	1,506,232
Revenue		817,518	1,615,358
Cost of revenue		96,636	3,651
Research and development expenses		3,064,115	3,784,255
Selling, general and administrative expenses, excluding depreciation and amortization	[1]
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]
Loss from operations	[3]	(2,343,233)	(2,172,548)
Other income (expense)	[4]
Benefit from income taxes		1,413	496,127
Loss from continuing operations		(2,341,820)	(1,676,421)
Income from discontinued operations, net of tax effect		1,449	88,673,053
Gain on sale of discontinued operations, net of tax effect		43,053
Net income (loss)		(2,297,318)	86,996,632
Capital expenditures
Other income (expense)	[4]
Benefit from income taxes		1,413	496,127
Net income (loss)		(2,297,318)	86,996,632
Diagnostics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		91,425	13,065,871
Diagnostics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		14,330	30,476
Diagnostics Segment [Member] | Royalty [Member]
Revenue from contract with customer		15,347	9,126
Diagnostics Segment [Member] | License [Member]
Revenue from contract with customer		307,174	100,000
Therapeutics Segment [Member]
Grant and other revenue		351,833	195,079
Revenue		351,833	195,079
Cost of revenue
Research and development expenses		1,157,766	729,587
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	78,606	34,484
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]
Loss from operations	[3]	(884,539)	(568,992)
Other income (expense)	[4]
Benefit from income taxes		534	129,936
Loss from continuing operations		(884,005)	(439,056)
Income from discontinued operations, net of tax effect
Gain on sale of discontinued operations, net of tax effect
Net income (loss)		(884,005)	(439,056)
Capital expenditures
Other income (expense)	[4]
Benefit from income taxes		534	129,936
Net income (loss)		(884,005)	(439,056)
Therapeutics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		24,763	49,001
Therapeutics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization
Therapeutics Segment [Member] | Royalty [Member]
Revenue from contract with customer
Therapeutics Segment [Member] | License [Member]
Revenue from contract with customer
Corporate Segment [Member]
Grant and other revenue
Revenue
Cost of revenue
Research and development expenses
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	7,469,144	10,895,301
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	150,385	240,166
Loss from operations	[3]	(7,619,529)	(11,135,467)
Other income (expense)	[4]	(5,321,270)	(3,912,679)
Benefit from income taxes		7,806	3,436,426
Loss from continuing operations		(12,932,993)	(11,611,720)
Income from discontinued operations, net of tax effect
Gain on sale of discontinued operations, net of tax effect
Net income (loss)		(12,932,993)	(11,611,720)
Capital expenditures		46,192	33,690
Other income (expense)	[4]	(5,321,270)	(3,912,679)
Benefit from income taxes		7,806	3,436,426
Net income (loss)		(12,932,993)	(11,611,720)
Corporate Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		6,878,129	7,634,237
Corporate Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		381	1,851
Corporate Segment [Member] | Royalty [Member]
Revenue from contract with customer
Corporate Segment [Member] | License [Member]
Revenue from contract with customer
[1]	General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments. Marketing and selling expenses are allocated to our individual reportable segments.
[2]	Depreciation and amortization is reflected in selling, general and administrative expenses ($150,385 and $240,166 for the years ended December 31, 2018 and 2017, respectively).
[3]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.
[4]	Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.

Note 19 - Agreements (Details T

Note 19 - Agreements (Details Textual)		Mar. 03, 2017$ / sharesshares	Mar. 31, 2017$ / sharesshares	Jul. 31, 2014USD ($)	Sep. 30, 2013	Dec. 31, 2011USD ($)	Nov. 30, 2009	Jan. 31, 2002USD ($)	Dec. 31, 2018USD ($)$ / shares	Dec. 31, 2017USD ($)$ / sharesshares
Common Stock, Par or Stated Value Per Share | $ / shares		$ 0.001							$ 0.001	$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	[1]								$ 1.15
Research and Development Expense, Total									$ 4,221,881	$ 4,513,842
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares									$ 2.50
Series NN Warrants [Member]
Class of Warrant or Right, Term			5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares			$ 1.50						$ 1.50
Series NN Warrants [Member] | UCSD [Member]
Class of Warrant or Right, Term		5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		1,000,000	1,000,000							1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 1.50
Reliable Supply Agreement [Member]
Long-term Contract for Supplies, Initial Term							10 years
Long-term Contract for Supplies, Option to Extend, Term							3 years
Long-term Contract for Supplies, Resolution Term							60 days
Purchases Under Manufacture and Supply Agreement									$ 0	$ 0
OsoBio Supply Agreement [Member]
Long-term Contract for Supplies, Resolution Term					60 days
Purchases Under Manufacturing Agreement									0	250,000
Gipharma Supply Agreement [Member]
Long-term Contract for Supplies, Initial Term					3 years
Long-term Contract for Supplies, Renewal Term					1 year
Purchases Under Service and Supply Master Agreement									0	14,000
Tc99m Tilmanocept License Agreement [Member]
License Issue Fee								$ 25,000
License Maintenance Fee								25,000
Minimum Annual Royalty								$ 25,000
Expanded Tc99m Tilmanocept License Agreement [Member] | Outside the Territory [Member] | Cost of Sales [Member] | License [Member]
Cost of Goods and Services Sold, Total									1,000	4,000
Amended and Restated Tilmanocept License Agreement [Member]
Research and Development Expense, Total									35,000	34,000
Tilmanocept License Agreement [Member]
License Issue Fee				$ 25,000
License Maintenance Fee				25,000
Minimum Annual Royalty				$ 25,000
Research and Development Expense, Total									250,000	253,000
Astra Zeneca Agreement [Member]
Milestone Payments, Maximum, Cash, Clinical Development and Regulatory Filing Milestones						$ 6,500,000
Milestone Payments, Maximum, Cash, Due Following Receipt of Regulatory Approvals and Initiation of Commercial Sales						11,000,000
Astra Zeneca Agreement [Member] | License [Member]
Cost of Goods and Services Sold, Total						$ 5,000,000
Alseres Pharmaceuticals Agreement [Member]
Research and Development Expense, Total									$ 0	$ 70,000
Ratio of Entitled Salary									4.25
Employment Agreement [Member] | Maximum [Member]
Loss Contingency, Estimate of Possible Loss									$ 2,000,000
[1]	Weighted average exercise price.

Note 20 - Employee Benefit Pl_2

Note 20 - Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Defined Contribution Plan, Cost	$ 40,000	$ 12,000

Note 21 - Supplemental Disclo_2

Note 21 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)	Nov. 20, 2018	Nov. 30, 2018	Mar. 31, 2017	Jan. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Nov. 30, 2017	Mar. 03, 2017
Interest Paid, Excluding Capitalized Interest, Operating Activities					$ 8,000	$ 7,400,000
Stock Issued During Period, Shares, Employee Benefit Plan					94,684	105,308
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution					$ 35,980	$ 53,707
Reclassification of Funds Invested				$ 200,000		200,000
Stock Issued During Period, Value, New Issues					3,000,000
Gain (Loss) on Extinguishment of Debt, Total					$ (5,291,616)	$ (4,201,668)
Common Stock [Member]
Stock Issued During Period, Shares, Employee Benefit Plan					94,684	105,308
Reclassification of Funds Invested
Stock Issued During Period, Shares, New Issues					18,320,610
Stock Issued During Period, Value, New Issues					$ 18,321
Former Chief Executive Officer and President [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues	18,500,000	18,500,000
Platinum Loan Agreement [Member] | Former Chief Executive Officer and President [Member]
Repayments of Convertible Debt		$ 2,200,000
Gain (Loss) on Extinguishment of Debt, Total		$ (1,000,000)
Platinum Loan Agreement [Member] | Former Chief Executive Officer and President [Member] | Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued		16,400,000
Stock Issued During Period, Value, New Issues		$ 3,200,000
IPFS [Member] | Notes Payable Issued for Prepayment of Insurance Premiums [Member]
Debt Instrument, Face Amount		$ 393,000					$ 396,000
Debt Instrument, Interest Rate, Stated Percentage		5.10%					4.00%
Series NN Warrants [Member] | UCSD [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			1,000,000			1,000,000		1,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value			$ 334,000			$ 334,000

Note 22 - Subsequent Events (De

Note 22 - Subsequent Events (Details Textual)	Mar. 07, 2019shares
Complaint By Dr. Goldberg Against Navidea and MT [Member] | MT [Member] | Subsequent Event [Member]
Litigation Case, Number of Shares of Super Voting Common Stock Failed to Issue	23,500,000